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Abstract 
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The hydrophobicity of many chemotherapeutic agents usually results in their 
nonselective passive distribution into healthy cells and organs causing collateral toxicity.  
Ligand-targeted drugs (LTDs) are a promising class of targeted anticancer agents.  The 
hydrophilicity of the targeting ligands in LTDs limits its nonselective passive tissue 
distribution and toxicity to healthy cells.  In addition, the small size of LTDs allows for better 
tumor penetration, especially in the case of solid tumors.  However, the short circulation half-
life of LTDs, due to their hydrophilicity and small size, remains a significant challenge for 
achieving their full therapeutic potential.  Therefore, extending the circulation half-life of 
targeted chemotherapeutic agents while maintaining their hydrophilicity and small size will 
represent a significant advance towards effective and safe cancer treatment.  Here, we present 
a new approach for enhancing the safety and efficacy of targeted chemotherapeutic agents.  
By endowing hydrophobic chemotherapeutic agents with a targeting moiety and a 
hydrophilic small molecule that binds reversibly to the serum protein transthyretin, we 
generated small hydrophilic drug conjugates that displayed enhanced circulation half-life in 
rodents and selectivity to cancer cells.  To the best of our knowledge, this is the first 
demonstration of a successful approach that maintains the small size and hydrophilicity of 
targeted anticancer agents containing hydrophobic payloads, while at the same time 
extending their circulation half-life.  This was demonstrated by the superior in vivo efficacy 
and lower toxicity of our conjugates in xenograft mouse models of metastatic prostate cancer.  
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CHAPTER 1: INTRODUCTION 
 
1.1.  Cancer 
Cancer is a major public health problem worldwide and is the second leading cause of 
death in the United States with over 1.7 million estimated new cases in 2019.  An estimated 
606,880 Americans will die from cancer in 2019, corresponding to almost 1,700 deaths per 
day1.  Cancer is a generic term for a collection of diseases mediated by abnormal cell growth 
and proliferation that can affect any part of the body1, 2.  The characteristic behavior of 
cancerous cells results after mutations that accumulate in various genes which control cell 
proliferation, leading to abnormalities in multiple cell regulatory systems2, 3.  Thus, instead of 
responding to signals that control cell behavior, cancer cells grow and divide uncontrollably, 
usually to form a tumor, invade normal tissues and organs, and eventually metastasize 
throughout the body2, 3.   
1.2. Chemotherapy 
The era of cancer drug development began in the 1940’s after using nitrogen mustard 
as a toxic treatment for cancer.  Failure of surgery and radiation therapy to eradicate 
metastatic cancer in the early years placed more emphasis on the development of drugs, 
biological molecules, and immune mediated therapies as chemotherapeutic agents4.  
Chemotherapy attacks tumors at the cellular level by interrupting processes or inhibiting 
substances required for cellular replication and survival.  The low budget government 
supported anticancer industry then progressed to develop antifolate chemotherapeutics (e.g. 
methotrexate) and insights in dose related cytotoxicity lead to the use of high dose 
conventional chemotherapy to increase cytotoxic efficacy.  However, discoveries of drug 
resistance and cell cycle phase specific drugs resulted in the use of combination therapies to 
treat cancer patients.  Most chemotherapeutic agents are designed to interfere with processes 
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inside a tumor cell.  These cytotoxic drugs should be hydrophobic enough to diffuse across 
cell membranes and reach their intracellular targets.  However, the hydrophobicity of these 
drugs will usually result in their nonselective passive distribution into healthy cells and 
organs resulting in collateral toxicity.  Therefore, strategies that minimize the toxicity of 
these cytotoxic agents toward healthy cells while maintaining their potency on tumor cells are 
highly desirable.  One attractive strategy for achieving the required therapeutic potency with 
minimal toxicity is through targeted cancer therapy5. 
1.3. Targeted Chemotherapy 
Targeted anticancer therapy is an exponentially growing class of chemotherapeutic 
agents with advantages over conventional anticancer drugs5.  These advantages are a result of 
selective targeting of the cytotoxic agent towards cancer cells over normal cells.  The 
selectivity is typically achieved by utilizing a targeting moiety that interacts specifically with 
a marker protein that is present on the surface of cancer cells.  The framework of targeted 
anticancer therapeutics is established through a chemical linker acting as a spacer between 
the cytotoxic payload and the targeting moiety.  A heterogeneous array of targeting 
components has been utilized and reported as targeting drug conjugates such as antibodies, 
proteins, peptides, peptidomimetics and small molecules5. 
1.3.1.  Antibody-Drug Conjugates (ADCs) 
Over the past decade, antibody-drug conjugates (ADCs) have gained enormous 
popularity in oncology therapeutics5.  Recent advances in antibody engineering and phage-
display technologies lead to the widespread use of monoclonal antibodies and antibody 
fragments in oncology therapeutics6.  Currently, the ADC brentuximab vedotin, 
ADCETRIS® has been approved by the FDA for the treatment of patients with classical 
Hodgkin lymphoma7.  Advantages of ADCs over conventional low molecular mass 
chemotherapeutic agents include their long circulation half-life (t1/2), and high specificity and 
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binding affinity for target tissues7.  However, failure of the majority of ADCs during clinical 
trials stems from their large molecular weight (MW ~150 kilodaltons; kDa) and protein 
structure.  These characteristics manifest into limited penetration of tumor tissue, particularly 
when the binding affinity of antigens to target receptors is high.  Both systemic and endocytic 
antibody clearance are culprits to decreased antibody penetration and hence failure of 
cytotoxic agent to saturate tumors8.  Furthermore, potential immunogenicity from acute 
anaphylactic reactions during infusion, tumor lysis and cytokine release syndrome have also 
been reported with the use of ADC9.  In addition, manufacturing and formulation limitations 
exist such as the lack of oral bioavailability, elaborate conjugation chemistry and high 
production cost.  Off-target toxicity has also been reported from many ADCs such as 
ADCETRIS, due to the premature release of the cytotoxic payload9.  While the large size of 
ADCs limits the nonselective distribution of the cytotoxic agent into healthy cells and tissues, 
it also reduces their rate of diffusion and extent of penetration into solid tumor tissues.  
Therefore, the majority of approved ADCs and the ones in clinical trials are used in 
hematologic cancers.  The limited number of ADCs used in the treatment of solid tumors led 
many to explore alternative, smaller-format drug conjugates with better tumor penetrating 
properties10-12. 
1.3.2. Low Molecular Weight Ligand-Targeted Drugs (LTDs) 
Ligand-targeted drugs (LTDs) that employ low-molecular weight hydrophilic small 
molecules or peptides as targeting moieties (e.g., vintafolide, etarfolatide, and 177Lu-PSMA-
617) are a promising new class of targeted cancer therapeutics5, 10.  The small size of LTDs 
(typically ~1 to 5 kDa) allows for better tumor penetration, especially in the case of solid 
tumors.  In addition, the hydrophilicity of the targeting ligand increases the overall 
hydrophilicity of the hydrophobic cytotoxic payload in the LTD which limits its nonselective 
passive tissue distribution and toxicity to healthy cells.  On the other hand, hydrophilic small 
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molecules are readily cleared through the kidneys within 30 min of injection (size cutoff for 
molecules to be cleared through glomerular filtration is ~30 kDa)13.  The short in vivo half-
life of LTDs (e.g., t1/2 for vintafolide and etarfolatide is ~25 min) reduces their exposure to 
receptor-expressing target tissues which prevents optimal tumor uptake10.  Therefore, dose-
limiting toxicity is observed due to the need for high doses and frequent administration5. 
1.4. Approaches for Enhancing the t1/2 of Therapeutic Agents 
Various approaches have been exploited to improve the t1/2 of small molecules and 
biotherapeutic drugs.  Covalent conjugation of proteins to polyethylene glycol (PEG) 
polymers, up to 40 kDa in size, was found to extend the in vivo t1/2 of proteins
14-16.  Polymers 
of PEG can be synthesized as linear or branched chains, with functional groups at the termini 
to facilitate a variety of conjugation procedures.  PEG is commonly conjugated to 
macromolecules such as proteins using different chemical strategies and reagents through 
stable or hydrolyzable linkages14-16.  Conjugation with PEG increases the hydrodynamic size 
of proteins and reduces glomerular filtration by the kidneys.  The hydrophilic mobile PEG 
moiety protects proteins from proteolysis by a dynamic process, where steric obstruction is 
created over the domain of the protein acting as the proteolytic substrate14-16.  However, this 
often comes at the expense of reduced binding affinity for the target14-16.  Consequently, PEG 
operates by altering the balance between pharmacodynamic and pharmacokinetic properties 
of the conjugate and attaining an extension in systemic exposure by compromising the 
binding affinity14-16.  In addition, the chemical conjugation process and heterogeneity of PEG 
typically yields complex product mixtures.  Furthermore, PEGylated molecules have been 
reported to cause renal tubular vacuolation and toxicity at high doses.  This is a result of the 
non-biodegradable nature of PEG, which is predominantly excreted unchanged by the 
kidneys17.  Induction of specific antibodies against PEG have also been reported in humans 
following administration of PEG-conjugated drugs, and pre-existing anti-PEG antibodies has 
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been identified in over 25% of the healthy population.  This translated to the rapid clearance 
of PEG-conjugated agents, and the risk of immunogenicity from PEG18.   
Conjugation of proteins to human serum albumin (HSA) has also improved the t1/2 of 
biotherapeutic agents such as insulin, and GLP-1.  HSA has a particularly long circulatory t1/2 
of 19 days, due to its high MW (~ 66.5 kDa: which is above the renal filtration cut-off of ~30 
kDA), and its specific interaction and recycling by neonatal Fc receptor (FcRn).  The large 
size and interaction with FcRn are also the reason for the extended serum t1/2 of Antibodies.  
Degradation of these proteins is postponed since they can bind FcRn with high affinity at low 
pH in the acidic endosome, deflecting them from the lysosomal degradation pathway.  Both 
HSA and antibodies are then recycled into the extracellular compartment where they are 
released at physiological pH, thus prolonging their t1/2.   
Therapeutic agents conjugated to HSA binding molecules (i.e. HSA tags) were found 
to have increased t1/2 which correlated proportionally to their binding affinity to HSA.  
However, due to the high binding affinity of these ligands to HSA, combined with the molar 
abundance of HSA (600 µM, 60 % of the total plasma protein pool), these HSA tags showed 
limited success in maintaining the therapeutics potency in vivo18.  An extended therapeutic 
t1/2 is desirable in certain chronic conditions such as a t1/2 of a few days in albumin—GLP-1 
conjugates for Type II diabetes.  However, sometimes it is undesirable to maintain 
therapeutic agents in circulation for prolonged periods, such as: (i) diagnostic applications 
[e.g. ProstaScint® (Cytogen Corporation, Princeton, NJ) 111indium  capromab pendetide, the 
only FDA approved radiolabelled anti-PSMA antibody for prostate cancer19 (t1/2 67.2 h)]; and 
(ii) certain peptide hormones, where prolonged exposure can cause serious side effects [e.g. 
Carbetocin, an obstetric drug used to control postpartum hemorrhage]20.  Conjugation of 
hydrophobic small-molecule albumin binders to radioimaging LTDs, containing hydrophilic 
DOTA chelators as the payload, has resulted in small conjugates with extended circulation 
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time and higher tumor uptake21.  Unfortunately, the albumin binding approach has not been 
successfully used with LTDs containing cytotoxic therapeutic payloads, where the warheads 
are typically ultra-potent hydrophobic small molecules (e.g., auristatins and maytansinoids).  
In this case, conjugation to the lipophilic albumin binders will increase the overall 
hydrophobicity of LTDs, which could make them prone to aggregation, micelle formation, or 
nonspecific diffusion and adsorption to off-target cells5, 10.  Therefore, extending the in vivo 
t1/2 of LTDs while maintaining their hydrophilicity and smaller size, which are crucial for 
selectivity and better tumor penetration, will represent a significant advance towards effective 
and safe cancer treatment.   
 
 
Figure 1.  Crystal structure of homo-tetrameric Transthyretin (TTR) bound to AG10.  
Monomers are colored individually (PDB ID: 4HIQ)22.  Two AG10 molecules are bound in 
the two thyroxine (T4) binding site in TTR. 
 
Our group has previously repurposed a derivative of the potent transthyretin (TTR; a 
56 kDa serum protein present at ~5 μM concentration, Figure 1) stabilizer, AG10 (1) for a t1/2 
extension approach for peptides22, 23.  AG10 is currently in Phase III clinical trials for TTR 
cardiac amyloidosis.  We developed linker-modified AG10 molecules that were conjugated to 
hydrophilic peptides (e.g., GnRH; Log P -3.6), which resulted in enhanced in vivo t1/2 of the 
peptide conjugates23.  We hypothesized that such an approach could be utilized to enhance 
the safety and efficacy of targeted anticancer agents containing hydrophobic payloads.  
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However, the linker we used in these first generation TTR binders was a lipophilic alkyl 
linker.  Therefore, conjugation of these TTR binders to a hydrophobic cytotoxic agent such as 
monomethyl auristatin E (MMAE; Log P +3.1) would not result in conjugates with an overall 
hydrophilic character.  We anticipate these conjugates to have nonselective passive diffusion 
into healthy cells.  We hypothesize that by increasing the hydrophilicity of the TTR ligands 
we could balance the effect of the hydrophobic MMAE in the conjugates.  This would confer 
overall hydrophilicity on cytotoxic conjugates, limiting their passive diffusion into healthy 
cells.   
Herein, we developed a second generation hydrophilic TTR ligands and demonstrated 
that they can be utilized in a targeted drug delivery system that enhances the safety and 
efficacy of targeted anticancer agents containing hydrophobic cytotoxic agents24.  We show 
that conjugation of the new TTR ligands to LTDs, targeting prostate cancer (PCa) cells, 
maintains the overall hydrophilicity of the conjugates.  Because of their hydrophilicity, and 
ability to bind to TTR, our conjugates displayed reduced toxicity towards healthy cells (by 
limiting non-selective passive tissue distribution)24.  In addition, the TTR ligands also allow 
these conjugates to bind reversibly to circulating endogenous TTR which increased their in 
vivo t1/2 in rats and mice.  Our approach has the unique advantage of maintaining the overall 
hydrophilicity and small size of these conjugates, while at the same time enhancing their 
circulation t1/2.  This was translated into superior in vivo efficacy of our conjugates, compared 
to typical LTDs, in mouse xenograft tumor models of metastatic PCa24. 
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CHAPTER 2: TRANSTHYRETIN: A CARRIER PROTEIN 
 
2.1.  Transthyretin 
Transthyretin (TTR) is a 56 kDa homo-tetrameric protein present in plasma and 
cerebrospinal fluid (CSF).  It is primarily synthesized by the liver and secreted into the blood, 
where it acts as a backup carrier of thyroxine (T4) and the primary carrier of holo (with 
retinol) retinol-binding protein (RBP) (Figure 2)25-27. 
 
 
Figure 2.  Schematic model of TTR bound to T4 and holo-Retinol–binding protein (holo-
RBP). 
 
2.2.  TTR Expression 
Plasma TTR is primarily synthesized in the liver, while TTR in the brain is 
synthesized by the choroid plexus.  TTR is also synthesized at lower amounts in several other 
tissues like retinal pigment epithelium of the eye, in the islets of Langerhans of the pancreas, 
intestine and meninges28.  TTR present in blood is produced and secreted by hepatocytes in 
the liver and normal TTR concentrations in healthy adults range between 20–40 mg/dL (3.5–
7 µM)29.  Therefore, when the liver is participating in acute phase response to injury, 
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malnutrition or chronic inflammation, there is a significant decrease in blood TTR levels.  
Hence, TTR levels are used as a marker for nutritional and inflammatory status in the clinic, 
especially in critically ill people where TTR would be more suitable to determine the 
progression of the patient’s health (due to its shorter t1/2  of 2 days) compared to blood protein 
with longer t1/2  such as albumin (t1/2 of 19 days). 
2.3.  TTR Structure 
Human TTR (TTR) is a 56 kDa homotetramer composed of four identical 127 amino 
acid residue subunits (~14 kDa per subunit) that form an extensive β-sheet structure30.  The 
four identical subunits (or monomers) of TTR assemble to form an internal channel at the 
weaker dimer–dimer interface where two thyroid hormones (T4) molecules could bind on the 
resulting tetramer28, 31.  Due to the presence of two other T4 transport proteins in blood, the 
TTR T4 binding sites remain largely unoccupied in humans (<1 % T4 bound) and among 
those occupied, only one site is filled as there is negative cooperativity in the binding of the 
second T4
32, 33.  The main function of TTR in the blood is the transport of holo-retinol binding 
protein (holo-RBP).  The binding site of holo-RBP on TTR is orthogonal to that of T4 (Figure 
2).  In addition to T4 and holo-RBP, several other pharmacologic agents and natural products, 
such as plant flavonoids, nonsteroidal analgesic drugs, and inotropic bipyridines, are strong 
competitors for T4 binding to TTR and have binding affinities greater than T4
28, 34.  
The structure of human wild-type TTR (WT-TTR) was one of the first proteins to be 
determined by X-ray crystallography26.  As of October 2015, there are about 241 reported 
TTR crystal structures and their variants listed in the Protein Data Bank (PDB, 
www.rcsb.org) representing five species of protein (human, rat, mouse, chicken, and fish).  
Studies have shown that the amino acid sequence of human WT- TTR is about 85% identical 
to that from various other species35.  Each subunit (monomer) of TTR consists of eight β-
strands, denoted A to H, and one short α helix.  These eight β-strands form two β-sheets, 
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comprised of the strands D-A-G-H and C-B-E-F, together creating an immunoglobulin-like 
β-barrel structure.  The two monomers dimerize mainly through H-strands forming 
antiparallel main-chain, main-chain interactions and through F-strands forming interactions 
between side chains and interconnecting water molecules.  Subsequently, these dimers 
interact through hydrophobic interactions between AB and GH loops forming a tetramer with 
a hydrophobic channel between the dimers where T4 binds
36.  The T4 binding site can be 
divided into three halogen-binding pockets (HBP), namely HBP1, HBP2, and HBP3. HBP1 
forms the outermost part of the channel, consisting of the side chains of Met13, Lys15 and 
Thr106.  HBP2 forms the middle portion of the channel consisting of the side chains of 
Leu17, Ala109, Leu110, and the hydrophilic main chain carbonyl groups of Ala108, and 
Ala109. HBP3 forms the last and innermost part of the channel, comprising the side chains of 
Ala108, Ala109, Leu110, Ser117, and Thr119.  The hydrophilic part of HBP3 is formed by 
the side chains of Ser117 and Thr119, the main chain carbonyl and amino groups of Ala108, 
Ala109, Leu110, and Thr118.  
2.4.  Physiological Function of TTR 
The most studied and acknowledged role of TTR in blood is the transport of retinol 
(vitamin A), however, recent studies have indicated that TTR may also play an important 
physiological role in proteolysis and transport of other miscellaneous ligands37. 
2.4.1.  TTR as a Transporter 
TTR is not the primary transporter of T4 (less than 1 % bound) and due to the 
presence of two other T4 transport proteins in blood, thyroxine-binding globulin (TBG) and 
albumin, the T4 binding sites remain largely unoccupied in humans
38, 39.  However, in the 
CSF, TTR is a major transporter of T4 in both humans and rats.  Interestingly, unlike in 
human blood, TTR is the major transporter of T4 in rats.  As there is negative cooperativity 
between the two T4 binding pockets, each TTR tetramer carries no more than one T4 
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molecule at a time40.  Retinol circulates in blood, bound to retinol binding protein (holo-
RBP), which is found in complex with TTR.  Evolution has proposed this association to 
facilitate RBP release from its site of synthesis in the endoplasmic reticulum and to prevent 
renal filtration of RBP41, 42.  The presence of retinol bound to RBP is essential for the 
formation of a stable complex with TTR43.  Structural studies revealed that the RBP binding 
site on TTR is orthogonal to TTR T4-binding pockets (Figure 2)
27.  In plasma, RBP binds to 
TTR in 1:1 molar ratio due to limited concentration of RBP available.  However, in vitro 
studies have shown that one TTR tetramer can bind up to two RBP molecules in presence of 
higher RBP concentration25.   
2.4.2. TTR as a Protease 
Apart from being a transporter of T4 and RBP, TTR has been identified to have 
proteolytic activity.  A fraction of TTR is known to associate with low density (LDL) and 
high  density lipoproteins (HDL) and about 1–2 % of the total circulating plasma TTR is 
bound to apoA-I, a major HDL apolipoprotein37.  Incubation of TTR and apoA-I at 
physiological conditions resulted in cleavage of C-terminus of apoA-I.  This cleavage by 
TTR reduces the ability of apoA-I to promote cholesterol efflux and increases apoA-I 
amyloidogenicity resulting in the development of atherosclerosis.  Recently, TTR was shown 
to have protective effect against amyloid beta (Aβ) deposition in Alzheimer’s disease (AD)44.  
Studies have shown that TTR could bind and cleave soluble Aβ and prevents the Aβ amyloid 
fibril formation in vitro44.  TTR cleaves Aβ in multiple positions generating shorter Aβ 
peptides displaying lower amyloidogenic potential.  Also, TTR was able to degrade 
aggregated forms of Aβ and may contribute in maintenance of normal Aβ levels in the brain.  
Among others, TTR can cleave neuropeptide Y (NPY) and may also contribute to 
neuropeptide homeostasis45. 
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2.4.3.  Miscellaneous Roles of TTR 
Several other physiological ligands were identified as TTR ligands, e.g. 
norepinephrine oxidation products, yellow compounds (carotenoids) like lutein and pterin, 
proteoglycans like perlecan, Lysosome-Associated Membrane Proteins (LAMP-1), 
Metallothioneins (MT2), flavonoid and xanthone derivatives)37. 
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CHAPTER 3: TTR-BASED TARGETED DRUG DELIVERY SYSTEM 
 
3.1.  General Concept 
Ligand-targeted drugs (LTDs) are typically BiFunctional Molecules (BFMs) that 
include a targeting ligand chemically linked to a therapeutic cytotoxic payload or imaging 
agent through a linker.  In order to overcome the poor pharmacokinetics of BFMs, while 
maintaining their hydrophilicity and small size, we outfitted these BFMs with an additional 
arm containing the hydrophilic TTR binding ligand (i.e. forming TriFunctional Molecules, 
TFMs).  To establish the proof of concept we designed these TFMs to deliver a hydrophilic 
small molecule imaging agent, Sulfo-Cyanine7 (Cy7; a water soluble indocyanine 7 dye for 
near infrared (NIR) in vivo imaging) or a lipophilic cytotoxic agent (monomethyl auristatin 
E, MMAE) to PCa cells overexpressing the prostate-specific membrane antigen (PSMA) 
(Figure 3).  PSMA is a transmembrane protein that is largely absent from healthy tissues but 
highly expressed on the surface of PCa cells and on new blood vessels that supply nutrients to 
many other types of cancers46, 47.  PSMA is also highly overexpressed in metastatic 
castration-resistant prostate cancer (mCRPC) and therefore targeting PSMA is considered a 
promising target both for imaging and chemotherapeutic agents48-50.  
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Figure 3.  Schematic illustration of the concept for the TTR-based targeted drug delivery 
approach.  TFMs are comprised TTR binding ligand (blue), PSMA ligand (black), and 
Payload (Cy7 or MMAE in red).  The hydrophilic TTR ligand allow TFMs to bind reversibly 
to circulating TTR, thereby reducing its renal clearance and enhancing its in vivo t1/2.  The 
overall hydrophilic nature of TFMs, in addition to binding to TTR, would also reduce the 
non-selective tissue distribution of TFMs to normal cells.  The PSMA targeting module 
allows the TFMs to selectively deliver the therapeutic payload of these TFMs to its 
intracellular targets in PSMA+ prostate cancer (PCa) cells.  The binding affinity of TFMs to 
PSMA is higher than its binding to TTR, which allows the TFMs to preferably interact with 
PSMA over TTR.  The linker system we used is too short to bring the two proteins in close 
proximity to each other, which prevents the formation of the ternary complex.   
 
3.2.  Development of Second-Generation Hydrophilic TTR Ligands 
We hypothesized that incorporating hydrophilic spacers in the TTR ligands will 
maintain the overall hydrophilicity of TFMs, limiting their passive diffusion into PSMA-
negative cells.  To assess the positions on linker system of the TTR ligands that could be 
amenable for modification, we performed in silico modeling studies that were focused on 
identifying possible interactions that could be formed between our new hydrophilic linkers 
and T4 pocket of TTR.  Our modeling studies suggested that by incorporating an amine group 
in linker we would accomplish two goals: (1) the amine group could potentially form an ionic 
interactions (salt bridges) with the two glutamic acid residues (Glu54/Glu54’) close to the 
surface of TTR; (2) the amine group will be highly protonated under physiological pH which 
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would increase the hydrophilicity of the new TTR ligands.  This modification would not only 
increase the affinity of the new ligands to TTR but will also increase the selectivity for TTR 
in serum by decreasing non-specific interactions with other serum proteins such as albumin.  
Modeling studies suggest that a linker length of ~8 Å will be needed to project the amine 
group close to Glu54/Glu54’.  The study showed that the putative salt bridges between the 
amine group and Glu54/Glu54’ does not interfere with the major interactions between the 
AG10 portion of the TTR ligand and inner TTR pocket.  Therefore, we attached the amine 
group through a six carbon linker to the meta-position of AG10 (1) to give TTR ligand 2 
(Figure 4b).  To investigate the hypothesized salt bridges with Glu54/Glu54’, we also tested 
the t-Boc-protected version of 2 that cannot form salt bridges with Glu54/Glu54’ (compound 
3, Figure 4c).  The binding affinity of ligand 3 to TTR was significantly lower than the 
binding affinity of ligand 2 (discussed below).  To investigate the effect of the steric bulk of 
the t-Boc group on the lower affinity, we also synthesized ligand 4 (containing a secondary 
amine group; Figure 4d) where short ethylene glycol spacer was added to 2.  Ligand 4 
maintained very good binding affinity and selectivity to TTR in buffer and serum, supporting 
the formation of the hypothesized salt bridges.  Therefore, we decided to use the hydrophilic 
ligand 2 as the main TTR binder in the synthesis of our TFMs. 
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Figure 4.  Crystal structure of TTR bound to AG10 (1) and modeled hydrophilic TTR 
ligands.  (a) Crystal structure of homo-tetrameric TTR bound to AG10, with monomers 
colored individually (PDB ID: 4HIQ).22  Two AG10 molecules are bound in the two 
thyroxine (T4) binding site in TTR.  (b-d) Close-up views of modeled TTR ligand 2, 3, and 4 
bound in one of the two TTR T4 pockets.  The putative salt bridges between the amine group 
of TTR ligands 2 and 4 with Glu54/Glu54’ of TTR are shown as dashed lines and the 
distances are given in Å.  
 
3.3.  Design and Synthesis of TFMs and BFMs 
The basic structure of the TFMs was intended to bring together four modules in a 
single construct: (i) TTR Ligand 2; (ii) PSMA targeting ligand; (iii) therapeutic/diagnostic 
payload; (iv) linker system.  We have designed and synthesized three TFMs (TFM1-3; Figure 
5).  TFM1 (5) has the imaging dye Cy7 attached through a non-cleavable linker for diagnostic 
purpose.  TFM2 (6) and TFM3 (7) have MMAE which is a highly potent hydrophobic 
antimitotic agent that inhibits cell division by blocking tubulin polymerization; with TFM3 
having a slightly longer and more hydrophilic spacer than TFM2.  Due to dose-limiting 
toxicities, MMAE is too toxic to be administered in its untargeted forms.  However, MMAE 
is an established targeted drug for a number of clinically used ADCs such as Adcetris51.  
MMAE was incorporated in TFM2 and TFM3 via a valine-citrulline dipeptide cleavable 
linker, a standard linker widely used in many successful ADCs including Adcetris52.  The 
linker is designed to be stable in the bloodstream and then release the active MMAE only 
when the TFMs are internalized into the targeted cancer cell’s endosome.  In all TFMs we 
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incorporated a known glutamate-urea-lysine ligand for targeting PSMA.  Glutamate-ureas are 
low-molecular weight and high affinity PSMA ligands, which selectively bind and then enter 
PSMA-expressing cells by PSMA endocytosis53, 54.  These ligands have been widely used for 
targeting both diagnostic and therapeutic agents to PSMA expressing PCa cells.  The total 
length of the spacer and linker system required for TFMs was determined from the distance 
between the proximal end of the bound Glutamate-ureas and TTR ligand to the unobstructed 
protein surface of PSMA and TTR, respectively (discussed below).  As controls for typical 
LTDs, we also synthesized two control BFMs: (i) BFM1 (8): a conjugate of the dye, Cy7, and 
the PSMA ligand connected through a non-cleavable linker; and (ii) BFM2 (9): a conjugate 
of MMAE and the PSMA ligand connected through a valine-citrulline cleavable linker 
(Figure 5).  Since BFM1 and BFM2 lack the TTR ligand 2, they would allow us to evaluate 
the effect of TTR recruitment on the performance of our TFMs.  
We have developed an efficient modular approach for the synthesis of TFM1-3 and 
BFM1-2 (Schemes 1 and 2).  Short ethylene glycol spacers were initially attached to ligand 2, 
which is required to clear the thyroxine (T4) binding site of TTR.  In addition, ethylene glycol 
spacers would further enhance the hydrophilicity of ligand 2.  The terminal end of the spacers 
was equipped with an azide group which was used to construct the TFMs by click coupling 
with an alkyne group that was introduced on the PSMA ligand.  This approach allowed the 
generation of TFMs with uniform composition and high purity (>95% purity; the fully 
described synthesis and HPLC purity analysis of TTR ligands, TFMs, and BFMs can be 
found in the Experimental Section). 
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Figure 5.  Chemical structures of TFMs and BFMs.  TFMs are comprised of four modules; 
TTR ligand 2 (blue), PSMA ligand (black), Payload (Cy7 or MMAE in red), and linker 
system (magenta).  BFM1 and TFM1 incorporate the imaging dye Cy7 attached through a 
non-cleavable linker.  MMAE was incorporated in BFM2, TFM2, and TFM3 via a valine-
citrulline dipeptide cleavable linker.  TFM3 has a slightly longer PEG spacer that increases 
its hydrophilicity compared to TFM2.  
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Scheme 1.  Synthesis of BFM1 and TFM1.  TTR Ligand 2 (Blue), PSMA Ligand (Black), 
Payload (Cy7 in Red), and Linker System (Magenta). 
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Scheme 2.  Synthesis of BFM2, TFM2, and TFM3.  TTR Ligand 2 (Blue), PSMA Ligand 
(Black), Payload (MMAE in Red), and Linker System (Magenta). 
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CHAPTER 4: RESULTS 
 
4.1.  Evaluation of Binding Affinity and Selectivity of Ligand 2 and TFM1-3 to TTR in 
Buffer and Serum 
The binding affinity (Kd) of ligand 2 and TFM1-3 to human TTR was evaluated using 
fluorescence polarization (FP) binding assay55.  Ligand 2 binds TTR with high affinity (Kd = 
48.9 nM; Figure 6a and Table 1), which could be due to the ability of 2 to form salt bridges 
with Glu54 (Figure 4b).  The putative salt bridges between the amine of 2 and Glu54 were also 
supported by the significant difference between the binding affinity of ligands 3 and 4.  While 
there was a 20-fold decrease in binding of 3 (where the amine group is masked by a t-Boc 
group) to TTR (Kd = 1040 nM), ligand 4 maintained very good binding affinity (Kd = 107.5 
nM).  The binding affinity of TFM2 to TTR (Kd = 497.7 nM) was similar to that of TFM3 (Kd 
= 553.4 nM), while the binding affinity of TFM1 was slightly higher (Kd = 374.1 nM) (Figure 
6a and Table 1).  It is clear that attaching the MMAE or Cy7 to 2 resulted in lower binding 
affinity to TTR.  However, this decrease in TTR binding affinity might be useful for allowing 
the molecules to preferably interact with PSMA.  
For our approach to work in vivo, TFMs must be able to selectively bind to TTR in 
the presence of >4,000 other human serum proteins.  We evaluated the selectivity of ligand 2 
and TFM1-3 binding to TTR in human serum using a well-established TTR serum 
fluorescent probe exclusion (FPE) selectivity assay56, 57.  The FPE assay is based on 
employing a fluorescent conjugate competition assay using a probe (covalent-probe) that 
binds selectively to TTR in serum and then covalently modifies the Lys15 amino acid at the 
periphery of the T4 pocket, creating a fluorescent conjugate.  Ligands that bind selectively to 
TTR in serum decrease the binding of covalent-probe to TTR, thus lowering the fluorescence.  
Our data showed that ligands 2 and 4 has a much higher TTR occupancy (80.4 ± 0.7% and 71 
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± 2.6%, respectively) compared to compound 3 (33.4 ± 0.8%) (Figure 6b,c). TFM1, TFM2, 
and TFM3 maintained very good binding selectivity to TTR in serum (57.6 ± 1.9%, 56.1 ± 
2.8%, and 63.6 ± 1.6% TTR occupancy, respectively).  Importantly, the performance of all 
TFMs was similar or better than that of TTR stabilizer, tafamidis58 (an approved drug for 
TTR amyloidosis; 50.8 ± 2.0% TTR occupancy) (Figure 6b,c). 
 
 
Figure 6.  Binding affinity of TFMs to TTR and PSMA in buffer and human serum and effect 
of TTR on extending the t1/2 of TFM1 and TFM3 in rats.  (a) Evaluation of the binding 
affinity of test compounds (0.01 µM to 20 µM) to TTR in buffer using fluorescence 
polarization assay.  The binding constant (Kd) values were calculated using the Cheng–
Prusoff equation from IC50 values.  Data represent the mean ± s.d. (n=3).  (b) Fluorescence 
change caused by modification of TTR in human serum (TTR concentration, ~5 μM) by 
covalent FPE probe monitored for 6 h in the presence of FPE probe alone (black circles) or 
probe and TTR ligands (colors; 10 μM).  The lower the binding and fluorescence of FPE 
probe, the higher is the binding selectivity of ligand to TTR.  (c) Bar graph representation of 
percent occupancy of TTR in human serum by TFMs in the presence of FPE probe measured 
after 3 h of incubation relative to probe alone.  Error bars indicate mean ± s.d. (n=4).  (d) 
Evaluation of the inhibitory activity of test compounds (1.5 nM to 100 μM) on PSMA-
catalyzed cleavage of N-acetylaspartylglutamate (NAAG).  Ki values were calculated using 
the Cheng–Prusoff equation from IC50 and Km values.  Data represent the mean ± s.d. (n=3).   
 
37 
Table 1 
Derived Kd Values and Calculated IC50 Values of Test Compounds from Fluorescence 
Polarization (FP) Binding Assay  
 
Test Compound IC50 (nM) Kd (nM) 
AG10 11.8 6.7 
Ligand 2 86.5 48.9 
Ligand 3 1840 1040 
Ligand 4 521.2 107.5 
TFM1 1813 374.1 
TFM2 2412 497.7 
TFM3 2682 553.4 
Note.  Data generated by Mark Miller (Alhamadsheh’s group) 
 
4.2.  Evaluation of the Binding Affinity of TFM1-3 to PSMA and the Ability of TFM1-3 
to Preferentially Interact with PSMA in the Presence of TTR 
TFMs must first bind to TTR in serum but should also be able to leave TTR and bind 
to PSMA on the surface of PCa cells.  This could be a mutually exclusive binding which is 
governed by the equilibrium constants of TFMs to TTR and PSMA (the desired outcome, 
assuming TFMs binding affinity is higher for PSMA than for TTR) or TFMs could bind both 
TTR and PSMA at the same time resulting in a drop in binding potency (the undesired outcome 
that is analogous to the PEGylation approach).  Therefore, we tested the ability of TFM1-3 to 
preferentially bind to PSMA over TTR.  
We used a standard PSMA enzymatic inhibition assay to test the activity of TFM1-3 
(Figure 6d and Table 2).  This assay measures the ability of test molecules to bind and inhibit 
(Ki) PSMA-catalyzed cleavage of the peptide substrate N-acetylaspartylglutamate (NAAG).  
The activity of the spacer-modified glutamate-urea-lysine ligand 22 (Figure 7) on PSMA (Ki 
of 9.5 nM) was close to that of the potent and selective PSMA competitive inhibitor, PMPA 
(Ki = 4.5 nM).   
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Figure 7.  Chemical structure of PSMA ligand 22.  Ligand 22 is a spacer-modified version of 
a known glutamate-urea-lysine PSMA ligand. 
 
Table 2 
Ki Values of PSMA Enzyme Inhibition Assay with Test Compounds BFM1-2, and TFM1-3 in 
the Absence and Presence of TTR 
 
Test Compound Ki (nM) 
PMPA 4.5 
Intermediate 19 9.5 
BFM1 20.7 
BFM2 7.0 
TFM1 32.8 
TFM1 + TTR 33.8 
TFM2 7.2 
TFM2 + TTR 11.3 
TFM3 14.7 
TFM3 + TTR 16.4 
Note.  Data generated by Mark Miller (Alhamadsheh’s group) 
 
The bifunctional molecules, BFM1 and BFM2, also bind to PSMA with high affinity 
(BFM1 Ki = 20.7 nM and BFM2 Ki = 7 nM).  There was a decrease in the binding affinity of 
TFM1 (with Cy7) to PSMA (Ki = 32.8 nM).  The binding affinity of TFM1 to PSMA did not 
change when excess TTR (1 µM TTR compared to 1 nM PSMA) was present in the assay (Ki 
= 33.8 nM).  A very similar pattern was observed for the MMAE conjugates, TFM2 (Ki = 7.2 
nM and 11.3 nM in the absence and presence of TTR, respectively) and TFM3 (Ki = 14.7 nM 
and 16.4 nM in the absence and presence of TTR, respectively).  Importantly, the binding 
affinity of TFM1-3 to PSMA (Kd ~7 to 33 nM) is higher than their binding to TTR (Kd for TTR 
~350 to 500 nM, determined by FP above), which should enable the TFMs to leave TTR in 
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serum and bind to PSMA on the surface of PCa cells.  We do not anticipate that a major fraction 
of TFMs could bind to PSMA and TTR simultaneously.  The formation of such ternary 
complex would have resulted in a large decrease in the binding affinity of TFMs to PSMA 
when the bulky TTR (56 kDa) is present.  In addition, modeling studies of TFM3 with both 
TTR and PSMA suggested that the linker we used (~16 Å) is too short to bring the two proteins 
in close proximity to each other (a linker of at least 21 Å is required to form the ternary complex 
between TTR, PSMA, and TFM3, Figure 8 and 9).  
 
 
Figure 8.  Modeling studies of TFM3 with both TTR and PSMA to determine the appropriate 
linker lengths.  (a) Chemical structure of TFM3 highlighting the carbons (Ca, Cx, and Cy) 
and nitrogen (Nx) atoms used for measurement of distance in the modeling.  (b) Structure of 
an optimized conformation of TFM3.  Atom labels and the distances of interest are shown. 
All the distances are in Å.  (c) We used the TTR:AG10 crystal structure (pdb id: 4HIQ)22 for 
TTR binding site measurement.  Two glutamine residues from chain A (E62) and chain A’ 
(E62’) are two residues highest from the center of the binding site.  Cx is the terminal carbon 
atom in the TTR ligand 2, which is at the highest position from the bottom of the binding 
pocket.  The scheme to the right shows the measured distances between oxygen atoms on E62 
and E62’, and Cx atom.  The distances are given in Å and the angle Cx-E62-E62’ is 21.0°.  
The distance from Cx to the surface of the TTR is at least 8.5 Å.  (d) We used the crystal 
structure of PSMA (pdb id: 2XEF)59 for PSMA binding site measurement.  The entrance of 
binding site is very wide and broad.  The highest three residues surrounding the entrance are 
identified as serine 263 (S263), lysine 445 (K445) and proline 565 (P565).  Position of Cy 
atom in the docked known glutamate-urea-lysine ligand for targeting PSMA was used to 
measure the distance to the surface of PSMA.  The scheme to the right shows the distances 
a b
c d
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(continued) between S263, K445, P565, and Cy atom.  The distance from Cy to the surface of 
PSMA was found to be minimum 12.7 Å.  In our linker system, the Cx-Cy distance is ~16 Å, 
which is too short to bring the two proteins in close proximity to each other.  A linker of at 
least 21 Å (8.5 Å + 12.7 Å) is required to form the ternary complex between TTR, PSMA, 
and TFM3.  (Data generated by: Dr. Hyun Joo) 
 
 
Figure 9.  Modeling studies of TFM3 with both TTR and PSMA suggested that the linker we 
used (~16 Å) is too short to bring the two proteins in close proximity to each other.  A linker 
of at least 21 Å is required to form ternary complex between TTR, PSMA, and TFM3.  
Schematic binding of TFM3 with TTR and PSMA.  TFM3 was super imposed onto ligand 2 
with TTR and onto the glutamate-urea-lysine ligand 22 docked with PSMA.  Hypothetical 
complex of TFM3 with TTR and PSMA is shown at the bottom of the figure.  Due to the 
short distance, this formation of the ternary complex between TFM3, TTR and PSMA is not 
favored.  (Data generated by: Dr. Hyun Joo) 
 
4.3.  TTR Extended the Circulation t1/2 of TFM1 in Rats 
Rat and mouse TTR (conc. in both ~ 5 µM)60, 61 has ~80% sequence homology with 
human TTR at the protein levels62, 63.  Most of the sequence differences occur in peripheral 
loop regions, while all the amino acids in the T4 binding sites, where TFMs bind, are 
conserved between rat, mouse, and human.  Therefore, we do not expect appreciable 
differences in the binding of TFMs between human and rat or mouse TTR.  In addition to 
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increasing the metabolic stability of TFMs in blood, we hypothesize that binding to TTR will 
also reduce glomerular filtration of TFMs due to the large size of TTR:TFM complex (~58 
kDa).  We have evaluated the pharmacokinetic properties of TFM1 and BFM1 (both 
containing the Cy7 dye with non-cleavable linker) in rats.  TFM1 and BFM1 (typical 
bifunctional ligand-targeted molecule; i.e. TFM1 without ligand 2) were administered as 
single IV doses (0.1 µmol/kg) to two groups of jugular vein cannulated male rats.  Blood 
samples were withdrawn from the jugular vein cannula at pre-determined time points 
(ranging from 5 min to 24 h) and concentrations of test compounds were quantitated in 
plasma (Figure 10).   
 
 
Figure 10.  Calibration curves used to quantitate (a) BFM1 and (b) TFM1 in rat plasma.  The 
data were generated using LI-COR Odyssey® CLx Imaging System. (Data generated by: 
Wabel Albusairi) 
 
Consistent with our hypothesis, the pharmacokinetic profile of TFM1 was markedly 
different than BFM1 (Figure 11).  The concentrations of TFM1 were significantly higher than 
BFM1 concentrations at any given time.  While there was no measurable amount of BFM1 
after 4 h, TFM1 was still present even after 24 h (Figure 11).  There was ~6.6 fold increase in 
the t1/2 of TFM1 compared to BFM1 (t1/2 = 5.03 ± 0.18 h vs 0.76 ± 0.04 h, respectively).  The 
mean residence time (MRT) was also ~16 fold higher for TFM1 compared to BFM1 (5.27 ± 
0.35 h and 0.32 ± 0.02 h, respectively).  This data strongly supports and validates our 
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approach that TTR recruitment can indeed enhance the t1/2 and pharmacokinetic profile of 
TFMs in vivo.  
 
 
Figure 11.  The pharmacokinetic properties of TFM1 and BFM1 were evaluated in male 
Wistar rats.  A single intravenous bolus dose of TFM1 or BFM1 (0.1 µmol/kg) was 
administered to two groups of male rats (n=3 for each group).  The concentration of test 
compounds in plasma was determined at different time points.  Concentrations are expressed 
as means ± s.d. of three biological replicates.  (Data generated by: Wabel Albusairi) 
 
 
4.4.  TTR Enhanced the Targeting of TFM1 to PSMA-Positive Cells in Xenograft 
Mouse Models of Metastatic Prostate Cancer 
We evaluated the in vivo tumor specificity of TFM1 and BFM1 in mice bearing PCa 
tumor xenografts.  Tumor models were generated by injecting LNCaP (PSMA+ lymph node 
prostate cancer; ∼106 PSMA copies/cell)64, 65 and DU145 (PSMA-)64 PCa cells 
subcutaneously into the flanks (left and right) of male athymic nu/nu mice.  Once the tumor 
volume was 100-150 mm3, mice were randomized in groups (with similar mean tumor 
volume) and injected with TFM1, BFM1 (17 nmol/kg) or vehicle (sterile saline) via tail vein 
injection.  Whole body imaging of mice was conducted at the designated time points after 
injection (1 h, 4 h, 24 h, 48 h, and 72 h) using LI-COR Odyssey® CLx Imaging System 
(Figure 12).  The in vivo imaging showed that the fluorescence signal for BFM1 in both 
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models was significantly reduced at 4 h postinjection and reduced to the background level at 
24 h.  In contrast, TFM1 maintained a very high fluorescence signal at 4 h and the signal was 
maintained for up to 48 h postinjection.  This data supports the in vivo pharmacokinetic 
profile of BFM1 and TFM1 observed in rats (Figure 11).   
The mice were sacrificed 72 h postinjection, and ex vivo tissue biodistribution 
analysis was performed by imaging of the excised tumors, liver, kidneys, heart, and blood 
samples.  These studies demonstrated that TFM1 and BFM1 accumulated predominantly in 
PSMA expressing LNCaP tumors, with no substantial fluorescence activity in other tissues 
except kidneys (Figure 13a).  The superior selectivity of TFM1 for PSMA+ tumors was also 
demonstrated by ex vivo imaging of excised tumors which showed a ~7 fold higher 
fluorescent signal in LNCaP compared to DU145 tumors (Figure 13b).  There was a ~3 fold 
enhanced uptake of TFM1 in LNCaP compared to BFM1. This indicates that the enhanced 
tumor uptake of TFM1 in LNCaP (PSMA+) tumors is due to the extended circulation t1/2 of 
TFM1 compared to BFM1, particularly since the binding affinity of BFM1 to PSMA in 
buffer was found to be higher than that of TFM1 (Ki = 20.7 nM and 33.8 nM, respectively). 
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Figure 12.  In vivo fluorescence imaging and ex vivo biodistribution and tumor targeting 
analysis of TFM1 in a xenograft mouse models of human metastatic prostate cancer.  
Representative in vivo images of male athymic nu/nu mice (n=3) bearing LNCaP (PSMA+) 
or DU145 (PSMA-) tumors, injected with vehicle, TFM1 or BFM1 at a dose of 17 nmol/kg 
via tail vein injection and scanned at 1 h, 4 h, 24 h, 48 h, and 72 h using LI-COR Odyssey® 
CLx Imaging System at excitation and emission wavelength 685 and 800 nm, respectively. 
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Figure 13.  Ex vivo biodistribution and tumor targeting analysis of TFM1.  (a) 72 h 
postinjection, mice were sacrificed, and ex vivo tissue biodistribution analysis was performed 
by imaging of the excised tumors, liver, kidneys, heart, and blood samples. AFU/mg of 
excised organs and blood after 72 h. Bar graph showing the respective mean (± s.d.) (n=6 for 
tumors or n=3 for other organs).  (b) Representative ex vivo images of excised LNCaP and 
DU145 tumors after 72 h and bar graph showing the respective mean (± s.d.) AFU/mg of 
excised tumors (n=6).  The significance of differences was measured by one-way ANOVA 
followed by Tukey’s multiple comparison test (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001). 
 
4.5.  TFM2 and TFM3 Efficiently Release MMAE Following Cathepsin B Cleavage in 
Buffer  
In order for TFMs to efficiently deliver MMAE to the cytosol, they must be cleaved 
by cathepsin B inside the lysosomes of target cancer cells. An in vitro enzymatic reaction 
model was constructed to mimic the in vivo cathepsin B cleavage of the valine-citrulline 
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linker connecting MMAE to TFM2 and TFM3.  The efficiency of MMAE release from the 
intact TFMs was assessed by treating TFM2 and TFM3 with cathepsin B (isolated from 
human liver) in buffer (pH 5.5; optimal pH of cathepsin B which is close to the pH in the 
lysosome) at 37°C.  The release of active MMAE from TFMs was analyzed by analytical 
HPLC as a function of time.  MMAE and individual intact TFMs were injected as standards 
to identify the corresponding species in the reaction mixture.  Incubation of BFM2, TFM2, 
and TFM3 (20 µM) with cathepsin B (100 nM) resulted in efficient MMAE release (98%) 
within 15 min (Figure 14 and Figure 15).  LC-MS/MS analysis of TFM3 further confirmed 
the release of MMAE and a fragment that contained compound 2 and PSMA ligand. 
 
 
Figure 14.  TFMs efficiently release MMAE after cathepsin B cleavage.  The valine-
citrulline dipeptide cleavable linker TFM3 is efficiently cleaved (within 15 min in buffer) by 
cathepsin B hydrolysis (step a) and spontaneous fragmentation (step b) of the para-
aminobenzylcarbamate intermediate. The formation of free MMAE and Fragment A after 
cleavage of TFM3 was confirmed by HPLC and LC-MS/MS analysis.  The HPLC spectrum 
is a representative of triplicate experiments (n=3).  (Data generated by: Wabel Albusairi) 
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Figure 15.  MMAE release from TFM2 and BFM2 upon cathepsin B cleavage.  (a) HPLC 
trace of free MMAE showing that no hydrolysis occurs by cathepsin B.  (b-c) The valine-
citrulline dipeptide cleavable linker in TFM2 and BFM2 is efficiently cleaved (within 15 min 
in buffer) by cathepsin B hydrolysis and spontaneous fragmentation of the p-
aminobenzylcarbamate intermediate.  The formation of free MMAE and Fragment A’ after 
cleavage of TFM2 was confirmed by HPLC and LC-MS/MS analysis. In the case of BFM2 
there was no Fragment A’ formed as it does not have the TTR-binding module in the 
structure.  The HPLC spectra are representatives of triplicate experiments (n=3).  (Data 
generated by: Wabel Albusairi) 
 
4.6.  Evaluating the Effect of TTR on the Cytotoxicity of TFMs against PSMA-
Expressing PCa Cells 
We have tested the activity of free MMAE and MMAE containing compounds 
(BFM2, TFM2, and TFM3) against LNCaP (PSMA+) and DU145 (PSMA-) cells.  MMAE 
was very potent against both LNCaP (IC50 = 1.06 nM) and DU145 (IC50 = 1.08 nM) (Figure 
16a).  The activity of BFM2, TFM2, and TFM3 on LNCaP (IC50 = 4.4 nM, 5.4 nM, and 3.5 
nM, respectively) was higher than their activity on DU145 (IC50 = 909 nM, 313 nM, and 243 
nM, respectively) (Figure 16b-d and Table 3).  This supports the targeting effect of these 
molecules on the PSMA+ LNCaP cells.  We then tested the cytotoxicity of all compounds in 
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the presence of TTR (1 µM).  There was no significant effect of TTR on the activity of all 
compounds towards LNCaP cells (IC50 = 2.1 nM, 8.0 nM, and 4.1 nM, for BFM2, TFM2, and 
TFM3, respectively).  In PSMA- DU145 cells, while there was no major effect of TTR on the 
activity of MMAE (IC50 = 0.9 nM) and BFM2 (IC50 = 784 nM), there was a 1.7 fold decrease 
in the activity of TFM2 (IC50 = 529 nM) and 3.2 fold decrease in the activity of TFM3 (IC50 
= 794 nM) when TTR was present.  
 
 
Figure 16.  TFMs have selective cytotoxicity on LNCaP (PSMA+) vs. DU145 (PSMA-) 
cells.   Selective uptake of BFM2, TFM2, and TFM3 by PSMA receptors and the effect of 
TTR on lowering the cytotoxicity of TFM2 and TFM3 on PSMA- cells.  MTT cell 
proliferation assay was used to determine the cytotoxicity of MMAE, BFM2, TFM2 and 
TFM3 against LNCaP (PSMA+) and DU145 (PSMA-) cell lines in the absence and presence 
of TTR.  (a) MMAE shows similar cytotoxicity against LNCaP and DU145 cell lines 
regardless of the absence and presence of TTR.  (b) Selective cytotoxicity of BFM2 against 
LNCaP (PSMA+) compared to DU145 (PSMA-) cell lines. The activity of BFM2 on these 
cell lines was similar in the absence and presence of TTR.  Selective cytotoxicity of (c) 
TFM2 and (d) TFM3 against LNCaP (PSMA+) compared to DU145 (PSMA-) cell lines.  
Both TFM2 and TFM3 were less toxic against DU145 (PSMA-) cell lines in presence of 
TTR.  Each time point is expressed as means ± s.d. (n=5). 
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Table 3 
IC50 Values of MMAE, BFM2, TFM2, and TFM3 Against LNCaP (PSMA+) and DU145 
(PSMA-) Cell Lines  
 
Test 
Compounds 
LNCaP cell line DU145 cell line 
IC50 (nM) 
without TTR 
IC50 (nM) 
with TTR 
IC50 (nM) 
without TTR 
IC50 (nM) 
with TTR 
MMAE 1.06 0.74 1.08 0.9 
BFM2 4.4 2.1 909 784 
TFM2 5.4 8.0 313 529 
TFM3 3.5 4.1 243 794 
 
Similar data was observed when we tested our molecules in HeLa cell (PSMA- cells 
derived from cervical cancer cells (Figure 17).  This data supports our hypothesis that TTR 
can indeed sequester (and lower the toxicity) of TFMs towards cells lacking the targeted 
receptor.  Importantly, the more hydrophilic TFM3 has the lowest activity against DU145 
(>200-fold lower activity than the activity against LNCaP), which as we hypothesized could 
be due to the lower passive diffusion across cell membrane.  Therefore, we decided to further 
evaluate the pharmacokinetic properties of TFM3 in rats and its efficacy in mice xenograft 
tumor models in comparison to BFM2. 
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Figure 17.  TFMs have selective cytotoxicity on HeLa cells (PSMA- cells derived from 
cervical cancer cells).  MTT cell proliferation assay was used to determine the cytotoxicity of 
(a) MMAE, (b) BFM2, (c) TFM2 and (d) TFM3 against HeLa cell line in the absence and 
presence of TTR. 
 
4.7.  TFM3 is More Stable than BFM2 in Rat and Mouse Serum and does not Interfere 
with holo-RBP-TTR Interaction 
The valine–citrulline linkers are stable in human serum.  However, it has been 
reported that these linkers can be hydrolyzed in mouse serum by extracellular 
carboxylesterase 1c (Ces1c)66.  Therefore, we assessed the stability of TFM3 and BFM2 in 
buffer, human, rat, and mouse sera before performing the in vivo pharmacokinetics and 
efficacy experiments (Figure 18, 19, and 20).   
No significant hydrolysis was observed for TFM3 and BFM2 (100% remaining) in 
buffer and human serum at 37°C for at least 24 h.  While there was some hydrolysis of the 
linker in rat serum, the majority of TFM3 (92.1 ± 1.1% and 80.4 ± 0.8% remaining after 12 h 
and 24 h, respectively) and BFM2 (82.1 ± 1.9% and 60.2 ± 1.8% remaining after 12 h and 24 
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h, respectively) were intact.  As anticipated, the valine–citrulline linkers of TFM3 and BFM2 
exhibited much lower stability in mouse serum (Figure 18d).  There was 56.4 ± 1.1% of 
TFM3 remaining after 12 h and 16.1 ± 0.8% remaining after 24 h (Figure 18d and 19d).  In 
contrast, BFM2 lost ~80% and 100% of the conjugated MMAE after 12 h and 24 h, 
respectively (Figure 18d and 20d). 
 
 
Figure 18.  Evaluation of the stability of TFM3 and BFM2 in PBS buffer, human serum, rat 
serum, and mice serum.  Stability of TFM3 and BFM2 was evaluated in (a) PBS; (b) human 
serum; and (c) rat serum.  Test compounds (50 μM) were incubated in PBS, human serum, or 
rat serum.  The concentration of test compounds remaining in respective media were 
determined at 0, 12 and 24 h using HPLC.  Bar graphs represent the mean of % compound 
remaining ± s.d. (n=3).  (d) Stability of TFM3 and BFM2 in mouse serum was evaluated at 
different time points until 24 h.  Test compounds (50 μM) were incubated in mouse serum.  
The concentration of test compounds remaining in respective medium were determined at 
different time points using HPLC.  Each time point represents the mean of % compound 
remaining ± s.d. (n=3).  The significance of the differences was measured by multiple t-test 
(unpaired, with Holm-sidak correction) (ns, not significant; *p ≤ 0.05; **p ≤ 0.01). 
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Figure 19.  HPLC traces for the stability study of TFM3 in (a) PBS; (b) human serum; (c) rat 
serum; and (d) mice serum at 0 h, 12 h, and 24 h. 
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Figure 20.  HPLC traces for the stability study of BFM2 in (a) PBS; (b) human serum; (c) rat 
serum; and (d) mice serum at 0 h, 12 h, and 24 h.  
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We investigated the effect of TTR on the enhanced stability of TFM3 over BFM2.  
Our data suggest that only ~20% protection for TFM3 is provided by TTR.  This is expected 
since the hydrolysis site on the valine–citrulline linker is at least 45 Å away from TTR 
(previous studies showed that 20 Å is the ideal linker length for maximum protection against 
peptides hydrolysis)23.  Therefore, we predict that the majority of the stabilizing effect against 
serum proteases is likely to come from the steric bulk of the TTR binding module.  
The main function of TTR is to transport holo-RBP (~1.5 μM)67.  TTR also acts as a 
back-up carrier of thyroxine (T4), however, due to the presence of two other T4 transport 
proteins in blood, these T4 sites remain largely unoccupied in humans (<1% T4 bound)
68.  The 
holo-RBP binding sites on TTR are positioned orthogonal to the non-overlapping T4 binding 
sites (where TFM3 binds), therefore the binding of holo-RBP to TTR is not affected by the 
presence or absence of T4.  In an effort to rule out the possibility that the extended linker in 
TFM3 would interfere with the holo-RBP binding to TTR, we performed a Western Blot 
assay in human serum (Figure 21).  Our results confirmed data reported in literature for T4, 
and showed that TTR can indeed interact with both TFM3 and holo-RBP in concert. 
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Figure 21.  Binding of ligand 2 and TFM3 to TTR does not interfere with the holo-RBP 
binding to TTR.  (a) Human serum (TTR concentration ~ 5 µM) was incubated with 
Thyroxine (T4), ligand 2, TFM3 (all compounds at 20µM final concentration) and DMSO in 
PBS buffer (pH 7) or with urea (8 M) buffer for 2 h at 37°C before cross-linking and 
immunoblotting.  The membrane was incubated with rabbit anti-RBP antibody and then with 
IRdye800 donkey anti-rabbit secondary antibody.  After incubation, the membrane was 
washed and scanned using LI-COR Odyssey® CLx Imaging System for quantification.  The 
membrane image is a representation of replicate experiment (n=3).  (b) Bar graph 
representing the mean (±s.d) (n=3) of %RBP displacement from TTR quantitated from three 
membranes.  The significance of the differences was measured by one-way ANOVA 
followed by Tukey’s multiple comparison test (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001). 
 
4.8.  TTR Extended the Circulation t1/2 of TFM3 in Rats 
We have evaluated the pharmacokinetic properties of TFM3 and BFM2 (both 
containing MMAE) in rats.  TFM3 (0.16 µmol/kg) and BFM2 (0.32 µmol/kg, twice the dose 
of TFM3) were administered as single IV doses to jugular vein cannulated male SD rats.  
Blood samples were withdrawn from the jugular vein cannula at pre-determined time points 
(ranging from 5 min to 24 h) and concentrations of test compounds were quantitated using a 
validated LC-MS/MS method (Figure 22).  
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Figure 22.  LC-MS/MS calibration curves used to quantitate (a) BFM2 and (b) TFM3 in rat 
plasma.  (c) LC-MS/MS chromatogram of TFM3, BFM2, and internal standard (IS) reference 
in rat plasma.  The identities of the compounds were determined using the following Q1/Q3 
transition masses for TFM3 (1237.9/684.3), BFM2 (965.7/684.4), and IS reference (defluro-
AG10) (273/92.9).  (Data generated by: Fang Liu) 
 
The pharmacokinetic profile of TFM3 was markedly different than BFM2 (Figure 
23).  The concentrations of TFM3 were significantly higher than BFM2 at any given time, 
despite the administration of twice as much BFM2.  While there was no measurable amount 
of BFM2 after 4 h, TFM3 was still present even after 24 h (Figure 23).  There was ~5.2 fold 
increase in the t1/2 of TFM3 compared to BFM2 (t1/2 = 3.84 ± 0.18 h vs. 0.73 ± 0.06 h, 
respectively).  Importantly, the MRT (~8-fold higher; 4.1 ± 0.68 h for TFM3 and 0.49 ± 0.1 h 
for BFM2) and AUC (exposure) (~3-fold higher; 4659 ± 561 nM.h for TFM3 and 1425 ± 206 
nM.h for BFM2) were significantly higher for TFM3 than BFM2.  This data is consistent 
with the data obtained for TFM1 and strongly supports and validates our approach that TTR 
recruitment can indeed enhance the t1/2 and pharmacokinetic profile of TFMs in vivo. 
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Figure 23.  The pharmacokinetic properties of TFM3 and BFM2 were evaluated in male 
Wistar rats.  BFM2 (0.32 µmol/kg) and TFM3 (0.16 µmol/kg) were evaluated following a 
single intravenous bolus dose to two groups of male rats (n=4 for each group).  The 
concentration of test compounds in plasma was determined at different time points.  
Concentrations are expressed as means ± s.d. of four biological replicates.  (Data generated 
by: Fang Liu and Wabel Albusairi) 
 
4.9.  TFM3 has Enhanced Antitumor Activity in a Xenograft Mouse Model of Human 
Metastatic Prostate Cancer 
Before performing the efficacy study, we did a preliminary evaluation of the toxicity 
of TFM3 and BFM2 in mice.  Four groups (n=4 per group) of CD-1 male mice received 
multiple i.p. doses of TFM3, BFM2, MMAE, or vehicle (300 nmol/kg every 3 days; total four 
doses) and the body weights of the animals were monitored for 12 days (Figure 24).  MMAE 
served as a control for untargeted cytotoxicity.  This dosing regimen is well under the 
reported maximum tolerated dose for MMAE (between 700 to 1400 nmol/kg)69 and also 
reported to be used for a number of ligand targeted MMAE conjugates70, 71.  Two additional 
groups (n=4 per group) were also administered higher doses of TFM3 and BFM2 (600 
nmol/kg).  The toxicity was evaluated by monitoring the body weight of the treated animals. 
Animals that lost >20% of their weight were euthanized.  As expected, there was a major 
decrease in the body weight of all mice treated with MMAE.  Our data showed that both 
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TFM3 and BFM2 were tolerated at the 300 nmol/kg dose.  There was a significant (p ≤ 
0.001) drop of the body weight of mice treated with BFM2 at the 600 nmol/kg.  From these 
studies, the 300 nmol/kg dose was selected to investigate the anticancer efficacy of our test 
compounds. 
 
 
Figure 24.  Preliminary evaluation of the toxicity of TFM3 and BFM2 in mice.  Repeat dose 
toxicity of TFM3 and BFM2 were determined in CD-1 male mice model.  Six groups of CD-
1 male mice (n=4 per group) received a single dose of test compounds [BFM2 (300 nomol/kg 
or 600 nmol/kg), TFM3 (300 nmol/kg or 600 nmol/kg), MMAE (300 nmol/kg) or vehicle] 
every 3rd day for nine days (total four doses).  The body weights of the animals were recorded 
every 3rd day.  Each time point represents mean % body weight change from day 0 ± s.d. 
(n=4).  The significance of the differences was measured by one-way ANOVA followed by 
Tukey’s multiple comparison test (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; 
****p ≤ 0.0001). 
 
We then examined the antitumor activity of test compounds in nude mice bearing 
human LNCaP (PSMA+) and DU145 (PSMA-) prostate tumors (Figure 25).  After xenograft 
tumors reached a volume of 100-150 mm3, mice were randomized into 4 treatment groups 
with similar mean tumor volume.  Equivalent molar quantities of TFM3, BFM2, MMAE (300 
nmol/kg), or saline (vehicle control) were administered (i.p.) every 3 days (total of 4 doses) to 
four groups of animals (n=6 per group).  Animal weights were measured throughout the study 
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as an indication of toxicity.  The antitumor activity of test compounds was evaluated by 
measuring the change in tumor size over time.  Our data showed that TFM3 effectively 
suppressed tumor growth of the LNCaP cells after the third dose (~70% decrease in tumor 
volume).  The antitumor activity of TFM3 was significantly (p ≤ 0.001) higher than BFM2, 
free MMAE, and vehicle (Figure 25a).  After this time point, the tumor size in the animals 
treated with TFM3 did not change significantly up to the end of the studied period (14 days) 
(Figure 25c).  The activity of MMAE was lower than both BFM2 and TFM3.  This is 
expected since MMAE is a lipophilic molecule that has a higher volume of distribution 
(8,400 ml/kg)72 compared to TFM3 (144 ml/kg), and therefore the effective dose reaching the 
tumor via untargeted delivery is low.  The extensive distribution of MMAE was clear from 
the dramatic decrease (>10%) in the body weight of animals after the first dose, which 
necessitated skipping the second dose for the MMAE group (Figure 25b).  On the other hand, 
no significant weight loss or any apparent signs of toxicity were observed for TFM3 and 
BFM2 treatment groups, and all mice survived the entirety of the in vivo study. 
We repeated the same efficacy experiment in the DU145 (PSMA-) tumor model 
(Figure 25d-f).  As expected, the tumor volumes of the TFM3 and BFM2 treatment groups 
were not significantly different compared to the vehicle treated group (Figure 25d).  The 
BFM2 and TFM3 treated animals did not show any sign of toxicities in terms of body weight 
(Figure 25e).  None of the treatment groups, except MMAE (p ≤ 0.05), showed significant 
anticancer effects in terms of end point tumor weight (Figure 25f).  At the same time, the 
MMAE treated animals showed significant signs of toxicities, i.e., body weight reduction, 
reduced food and water intake, and difficulties in movement.  Due to the signs of severe 
toxicity, the third dose of MMAE was not administered in DU145 model.  Unscheduled 
euthanasia was carried out for two MMAE treated animals on day nine and twelve during the 
study due to a reduction of greater than 20% of body weight and moribund symptoms.  
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Figure 25.  Antitumor efficacy of TFM3 and BFM2 in LNCaP (PSMA+) and DU145 
(PSMA-) xenograft mouse models of metastatic PCa.  (a) Male athymic nu/nu mice (n=6) 
with LNCaP (PSMA+) tumors received TFM3, BFM2, MMAE, or vehicle at a dose of 300 
nmol/kg via i.p. injection as indicated by black (for TFM3, BFM2, or vehicle) or green (for 
MMAE) arrows.  Each point represents mean (± s.d.) tumor volume (mm3).  (b) Mean (± s.d.) 
% body weight changes from the beginning of treatment in the same mice with LNCaP 
tumors.  (c) Mean (± s.d.) weight of excised LNCaP tumors from each treatment group after 
14 days.  (d) Male athymic nu/nu (n=6) mice with DU145 (PSMA-) tumors received TFM3, 
BFM2, MMAE, or vehicle at a dose of 300 nmol/kg via i.p. injection as indicated by black or 
green arrows.  Each point represents mean (± s.d.) tumor volume (mm3).  (e) Mean (± s.d.) % 
body weight changes from the beginning of treatment in the same mice with DU145 tumors.  
(f) Mean (± s.d.) weight of excised DU145 tumors from each treatment group after 14 days.  
The significance of differences was measured by one-way ANOVA followed by Tukey’s 
multiple comparison test (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 
0.0001). 
 
Summarizing the results of the efficacy experiments, one can conclude that 
incorporating the TTR ligand 2 in TFM3 significantly limited the toxicity of MMAE on 
healthy tissues, and at the same time substantially enhanced the antitumor efficacy of TFM3 
compared to BFM2.  This indicates that the enhanced tumor uptake of TFM3 in LNCaP 
(PSMA+) tumors is due to the prolonged blood circulation and exposure (AUC) of TFM3 
compared to BFM2, especially since the binding affinity of BFM2 to PSMA in buffer (Ki = 
7.2 nM) and its activity on LNCaP (PSMA+) cells (IC50 = 2.1 nM) are slightly higher than 
that for TFM3 (Ki = 16.4 nM and IC50 = 4.1 nM).  
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CHAPTER 5: DISCUSSION 
 
Small-format LTDs have several advantages over traditional non-targeted therapeutic 
agents.  However, the poor pharmacokinetic profile of these molecules remains an important 
issue that is yet to be resolved.  Therefore, strategies that enhance the pharmacokinetic 
properties of LTDs, while retaining their more effective tumor penetrating properties, could 
at last make these small-size conjugates a viable alternative to targeted large macromolecules 
that are disproportionately biased towards hematologic cancers over solid tumors.  While 
much of the effort in this field is focused on maintaining the small size and hydrophilicity of 
LTDs for efficient and selective penetration into solid tumor tissues, the trade-off is lower 
overall tumor uptake and lower in vivo efficacy due to rapid systemic clearance.   
In this study, we have developed a new concept and platform approach, which 
combines advantages from both large macromolecules (e.g., extended circulation t1/2) and 
small LTDs (e.g., high tumor penetration and hydrophilicity).  Endowing targeted 
chemotherapeutic agents with the small and hydrophilic TTR ligand 2 allows the generation 
of hydrophilic small TFMs (<3 kDa) that, in contrast to typical LTDs, have enhanced 
pharmacokinetic and efficacy profiles.  The modular design of the TFMs allows each TFM 
component to be optimized without dramatically affecting the performance of other modules.  
The smaller size of TFMs could offer a number of additional advantages such as lower 
antigenicity, lower production cost, and chemical stability.  The promising pharmacokinetics 
and efficacy suggest that TFM3 may provide a valuable lead for developing next-generation 
PSMA-targeted LTDs as potential therapeutics for mCRPC, a disease that is currently 
incurable.  To the best of our knowledge, this is the first demonstration of a successful 
approach that not only extends the circulation t1/2 but also maintains the smaller size and the 
hydrophilicity of targeted anticancer agents containing hydrophobic payloads.  
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CHAPTER 6: CONCLUSION 
 
The success of our approach in delivering both hydrophilic Cy7 and hydrophobic 
MMAE to the intracellular compartment of cancer cells indicates that this approach could be 
utilized for other small molecules targeting many types of cancers, as well as other diseases.  
We envision that the new TTR ligands we developed herein to be potentially useful for 
enhancing the pharmacokinetic properties and hydrophilicity of various biomolecules without 
significantly increasing their size.  This should broaden the scope and utility of our approach. 
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CHAPTER 7: EXPERIMENTAL SECTION 
 
7.1.  Materials and Reagents 
7.1.1.  Materials for Chemical Synthesis 
All reactions were carried out under an argon or nitrogen atmosphere using dry 
solvents under anhydrous conditions, unless otherwise noted.  The solvents used   were   ACS   
grade   from   Fisher.  Yields   refer   to chromatographically and spectroscopically (1H NMR 
and 13C NMR) homogeneous materials, unless otherwise noted.  Reagents were purchased 
from Aldrich and Fisher, and used without further purification.  Reactions were monitored by 
thin-layer chromatography (TLC) carried out on EMD Millipore® silica gel 60 coated with 
fluorescent indicator F254 TLC plates (cat # 5737-7), using UV light and iodine chamber as 
visualizing agents.  Normal phase flash column chromatography was carried out using Combi 
Flash® Rf+ Lumen instrument (Teledyne ISCO) with High Performance Silica Flash Column 
(RediSep® Rf+ Gold), Preparative thin-layer chromatography (PTLC) separations were 
carried out on Analtech® 2mm (60F-254) (cat # 02015).  1H NMR and 13C NMR spectra were 
recorded on a Jeol JNM−ECA600 spectrometer and calibrated using residual undeuterated 
solvent as an internal reference.  High-resolution mass spectra (HRMS) were determined by 
JEOL AccuTOF DART using Helium as an ionization gas and polyethylene glycol (PEG) as 
an external calibrating agent.  Coupling constants (J) were expressed in Hertz. 
7.1.2.  Materials and Reagents for In Vitro and In Vivo Analysis 
Prealbumin from human plasma (human TTR) was purchased from Sigma (Sigma: 
#P1742).  Amplex® Red Glutamic Acid/Glutamate Oxidase Assay Kit (Invitrogen, Fisher 
Scientific; Molecular Probes, A12221).  N-acetylaspartylglutamate (NAAG; MP 
Biomedicals, ICN15303625), rhPSMA (R&D Research, 4234ZN010). rhPSMA (20 μM in 
reaction buffer; R&D Research, 4234ZN010), PMPA obtained from Tocris (cat # 13-801-0).  
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Human   prostate carcinoma cell lines LNCaP (PSMA+) (ATCC CRL-1740) and DU145 
(PSMA-) (ATCC HTB-81) cell lines were obtained from American Type Culture Collection 
(ATCC), Manassas, USA.  Cathepsin B from human liver was purchased from Calbiochem, 
EMD Millipore Corp (# 219362-50UG).  Rabbit anti-RBP4 antibody was purchased form 
Abcam (#ab154914).  IRdye800 donkey anti-rabbit secondary antibody was purchased from 
LI-COR Biosciences (#926-32213).  Human serum was purchased from Sigma (#H4522) 
[TTR concentration in serum was measured using nephelometric analyzer (28 mg/dL or 5 
µM)].  Glutaraldehyde was purchased from Sigma (#G5882).  RPMI-1640 Medium 
(HyClone, Utah, USA), fetal bovine serum (Gemini), penicillin/streptomycin (100 unit/ml 
and 100µg/ml; (Gibco, NY, USA) and L-Glutamine (Glutamax-100X, Gibco, NY, USA).  
CellBIND® 96 well clear plates (CLS3340-50EA) were purchased from Corning®.  CellTiter 
96 non-radioactive cell proliferation assay kit (cat# G4000, Promega, WI, USA) was used to 
perform the MTT (3-(4,  5-dimethylthiazol- 2-yl)-2,  5-diphenyltetrazolium  bromide) assay 
for the test compounds in both the cell lines.  
7.2.  Methods  
7.2.1.  Chemical Synthesis and HPLC Purity Analysis 
Preparative HPLC Method for Purification of TFMs and BFMs.  The purification 
was performed on a Waters Delta 600 HPLC system connected to a photodiode array detector 
operating between the UV ranges of 210 – 600 nm, using Waters Masslynx V4.1 software.  
The HPLC analysis was performed on an XBridgeTM Prep C18 Column (10 x 100 mm, 5 μM) 
at ambient temperature upon injection of 5 ml of each sample to obtain the chromatogram at 
254 nm UV absorbance.  The mobile phase was composed of solvent A consisting methanol-
water (5:95, v/v) containing 0.1% formic acid and solvent B consisting methanol-water (95:5, 
v/v) containing 0.1% formic acid and delivered at a flow of 2.0 ml/min.  The HPLC program 
was a gradient separation increasing linearly from 0-100 % solvent B. 
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Analytical HPLC Method for Evaluating the Purity of TFMs and BFMs.  
Detailed HPLC information of key compounds (traces, retention times, and %purity) are 
included below.  The analysis of key compounds purity (>95% for all compounds) was 
performed using C18 and C4 reverse-phase HPLC columns on Agilent 1100 series HPLC 
system connected to a diode array detector operating between the UV ranges of 200 – 400 nm 
and quantified using Agilent Chemstation software.  The HPLC analysis was performed on a 
Waters™ XBridge C18 column (4.6 X 150 mm, 5μm) or a Waters™ Symmetry300 C4 
column (2.1 X 150 mm, 5 µm), eluting at 0.5 ml/min, at ambient temperature upon injection 
of 50 μl of each sample to obtain the chromatogram at 254nm UV absorbance.  The mobile 
phase was composed of solvent A consisting methanol-water (5:95, v/v) containing 0.1% 
formic acid and solvent B consisting methanol-water (95:5, v/v) containing 0.1% formic acid.  
The HPLC program for the C18 column was a gradient method increasing linearly from 0-
100 % solvent B at 10-20 minutes, followed by isocratic at 100% solvent B until 35 min, and 
then back to 0% of B at 37 min.  For the C4 column, the method was 0-100 % solvent B at 
10-20 minutes, followed by isocratic at 100% solvent B until 28 min, and then back to 0% of 
B at 30 min. 
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Scheme 3.  Synthesis of TTR ligand 2. a) tert-butyl (6-bromohexyl)carbamate, K2CO3, KI, 
MeCN, reflux, 16 h; b) 1,3- dibromopropane, K2CO3, DMF, rt, 16 h; c) i. acetylacetone, 
DBU, benzene, rt, 3 days; ii. hydrazine hydrate, ethanol, 90°C, 4 h; d) NaOH, MeOH/water, 
50°C, 14 h; e) 20% TFA in DCM, rt, 3 h. 
 
 
 
Methyl 3-((6-((tert-butoxycarbonyl)amino)hexyl)oxy)-5-hydroxybenzoate (23).  
To a solution of methyl 3,5- dihydroxybenzoate (0.77 g, 4.58 mmol, 1 equiv) and tert-butyl 
(6-bromohexyl)carbamate (1.15 g, 4.12 mmol, 0.9 equiv) in anhydrous MeCN (30 ml) was 
added K2CO3 (1.27 g, 9.16 mmol, 2 equiv) and KI (0.15 g, 0.92 mmol, 0.2 equiv).  The 
suspension was heated to reflux for 16 h, filtered, and the solid was rinsed with MeCN.  The 
filtrate was concentrated under reduced pressure.  Water was added to the residue and the 
aqueous phase was extracted with EtOAc (150 ml), washed with brine (3x50 ml) and dried 
with anhydrous sodium sulfate.  The solution was filtered and concentrated and the residue 
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was purified by flash column chromatography (silica gel, 1-10% EtOAc/hexanes) to afford 
compound 23 (1.06 g, 70% yield); 1H NMR (CD3OD, 600 MHz) δ 6.99-6.98 (m, 2H), 6.54 (t, 
1H, J = 2.4 Hz), 3.96 (t, 2H, J = 6.6 Hz), 3.84 (s, 3H), 3.02 (t, 2H, J= 7.0 Hz), 1.77-1.73 (m, 
2H), 1.50-1.35 (m, 6H), 1.40 (s, 9H); 13C NMR (CD3OD, 150 MHz): δ 25.48, 26.25, 27.44, 
28.88, 29.57, 39.94, 51.27, 67.76, 78.47, 106.14, 106.50, 108.57, 131.71, 157.26, 158.53, 
160.40, 167.20 ppm. HRMS (DART) m/z: calcd for C19H29NO6+ H
+ 368.2068; found 
368.2070 (M + H)+. 
 
 
 
Methyl 3-(3-bromopropoxy)-5-((6-((tert-butoxycarbonyl)amino)hexyl)oxy)- 
benzoate(24).  To a solution of 23 (565.9 mg, 1.54 mmol, 1 equiv) and 1,3-dibromopropane 
(0.78 ml, 7.7 mmol, 5 equiv) in DMF (5 ml) was added K2CO3 (256 mg, 1.85 mmol, 1.2 
equiv).  The reaction mixture was stirred at room temperature for 16 h. The mixture was 
diluted with EtOAc (150 ml), washed with brine (3x50 ml) and dried with anhydrous sodium 
sulfate.  The solution was filtered and concentrated. The residue was purified by flash column 
chromatography (silica gel, 1-10% EtOAc/hexanes) to afford compound 24 (646 mg, 86% 
yield); 1H NMR (CD3OD, 600 MHz) δ 7.12-7.11 (m, 2H), 6.69 (t, 1H, J = 2.4 Hz), 4.11 (t, 
2H, J = 5.9 Hz), 3.97 (t, 2H, J = 6.4 Hz), 3.86 (d, J= 2.3 Hz, 3H), 3.60 (t, 2H, J= 6.5 Hz), 3.02 
(t, 2H, J = 7.0 Hz), 2.30-2.26 (m, 2H), 1.79-1.74 (m, 2H), 1.50-1.35 (m, 6H), 1.40 (s, 9H); 
13C NMR (CD3OD, 150 MHz): δ 25.47, 26.23, 27.45, 28.85, 29.13, 29.57, 32.15, 39.93, 
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51.41, 65.59, 67.93, 78.42, 106.03, 107.22, 107.65, 131.84, 157.26, 160.03, 160.42, 166.96 
ppm. HRMS (DART) m/z: calcd for C22H34BrNO6+ H
+ 488.1643; found 488.1629 (M + H)+. 
 
 
 
Methyl 3-((6-((tert-butoxycarbonyl)amino)hexyl)oxy)-5-(3-(3,5-dimethyl-1H-
pyrazol-4-yl)propoxy)benzoate (25).  A solution of 24 (618.74 mg, 1.27 mmol, 1 equiv) in 
benzene (5 ml) was added dropwise to a solution of acetyl acetone (0.26 ml, 2.54 mmol, 2 
equiv) and DBU (0.38 ml, 2.54 mmol, 2 equiv) in benzene (7 ml).  The reaction mixture was 
stirred at room temperature for 3 days. The mixture was filtered and passed through a pad of 
silica gel.  The solvent was removed and the residue was dissolved in ethanol (5 ml).  
Hydrazine hydrate (0.17 ml, 3.18 mmol, 2.5 equiv) was added and the reaction was heated 
(90°C) under reflux for 4 h.  The reaction was concentrated and purified by flash column 
chromatography (silica gel, 1-20% MeOH/CH2Cl2) to afford compound 25 (200 mg, 31% 
yield) in two steps; 1H NMR (CD3OD, 600 MHz) δ 7.10-7.08 (m, 2H), 6.65 (t, 1H, J = 2.4 
Hz), 3.96 (t, 2H, J = 6.4 Hz), 3.89 (t, 2H, J = 6 Hz), 3.86 (s, 3H), 3.02 (t, 2H, J = 7.2 Hz), 
2.55 (t, 2H, J = 7.2 Hz), 2.11 (s, 6H), 1.92-1.87 (m, 2H), 1.78-1.73 (m, 2H), 1.50-1.35 (m, 
6H), 1.40 (s, 9H); 13C NMR (CD3OD, 150 MHz): δ 18.48, 25.48, 26.24, 27.45, 28.86, 29.42, 
29.57, 39.93, 51.39, 66.53, 67.91, 78.46, 105.92, 107.26, 107.30, 113.86, 131.79, 157.25, 
160.24, 160.41, 167.00 ppm. HRMS (DART) m/z: calcd for C27H41N3O6+ H
+ 504.3068; 
found 504.3054 (M + H)+. 
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3-((6-((tert-butoxycarbonyl)amino)hexyl)oxy)-5-(3-(3,5-dimethyl-1H-pyrazol-4-
yl)propoxy)benzoic acid (3).  To a solution of 25 (115.76 mg, 0.23 mmol, 1 equiv) in a 
mixture of MeOH (4 ml) and water (1 ml) was added NaOH (18.4 mg, 0.46 mmol, 2 equiv).  
The reaction mixture was heated at 50°C for 14 h and then concentrated under reduced 
pressure.  The residue was extracted with 50% MeOH/EtOAc. The combined organic extracts 
were concentrated under reduced pressure and the product was subject to purification by 
preparative HPLC to afford compound 3 (82.2 mg, 73% yield); (98% purity by HPLC): tR 
(column) (C18) = 25.2 min; tR (C4) = 21.6 min. 
1H NMR (CD3OD, 600 MHz) δ 7.10-7.08 
(m, 2H), 6.47 (t, 1H, J = 2.3 Hz), 3.95 (t, 2H, J = 6.4 Hz), 3.88 (t, 2H, J = 5.9 Hz), 3.02 (t, 2H, 
J= 7.0 Hz), 2.55 (t, 2H, J = 7.2 Hz), 2.11 (s, 6H), 1.91-1.86 (m, 2H), 1.73-1.77 (m, 2H), 1.50-
1.35 (m, 6H), 1.40 (s, 9H); 13C NMR (CD3OD, 150 MHz): δ 18.50, 25.57, 26.31, 27.46, 
29.00, 29.57, 39.99, 66.16, 67.65, 78.43, 103.58, 107.14, 107.17, 114.00, 139.98, 157.25, 
159.71, 159.84, 173.74. HRMS (DART) m/z: calcd for C26H39N3O6+ H
+ 490.2912; found 
490.2935 (M + H)+. 
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3-((6-Aminohexyl)oxy)-5-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy) benzoic acid 
(2).  To a solution of 3 (60 mg, 0.123 mmol, 1 equiv) was added a mixture containing TFA 
and CH2Cl2, (1:4 ratio) (3 ml).  The reaction was stirred at room temperature for 3 h.  The 
solution was concentrated under reduced pressure and purified by preparative HPLC to afford 
compound 2 (41.65 mg, 87% yield); (98% purity by HPLC): tR (column) (C18) = 21.6 min; tR 
(C4) = 17.7 min. 1H NMR (CD3OD, 600 MHz) δ 7.10 (d, 2H, J = 2.4 Hz), 6.55 (t, 1H, J = 
2.4), 3.97 (t, 2H, J  = 6 Hz), 3.88 (t, 2H, J  = 6 Hz), 2.91 (t, 2H, J = 7.2 Hz), 2.55 (t, 2H, J = 
7.2 Hz), 2.11 (s, 6H), 1.91-1.87 (m, 2H), 1.79-1.75 (m, 2H), 1.68-1.63 (m, 2H), 1.54-1.49 (m, 
2H), 1.47-1.41 (m, 2H); 13C NMR (CD3OD, 150 MHz): δ 9.23, 18.51, 25.31, 25.80, 27.18, 
28.62, 29.50, 39.33, 48.52, 66.37, 67.57, 104.82, 107.34, 107.38, 113.94, 135.97, 141.96, 
160.04, 170.73 ppm. HRMS (DART) m/z: calcd for C21H31N3O4+ H
+ 390.2388; found 
390.2375 (M + H)+. 
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Chemical Synthesis of 2PEG-modified ligand 2 (compound 11). 
 
 
Scheme 4.  Synthesis of 2PEG-modified ligand 2 (compound 11). a) NaH, 1,6-
dibromohexane, DMF, rt, 3 h; b) K2CO3, 3,5-dihydroxybenzoate, DMF, rt, 16 h; c) 
K2CO3,1,3-dibromopropane, DMF, rt, 16 h; d) i. acetylacetone, DBU, benzene, rt, 3 days; ii. 
hydrazine hydrate, ethanol, 90oC, 4 h; e) NaOH, MeOH/water, 50oC, 14 h. 
 
 
 
tert-Butyl (2-(2-azidoethoxy)ethyl)(6-bromohexyl)carbamate (26).  To a solution 
of N-[2-(2-azidoethoxy)ethyl]-,1,1-dimethylethyl ester (9 g, 39.11 mmol, 1 equiv) in 
anhydrous DMF (100 ml) was added NaH (3.13 g, 78.21 mmol, 2 equiv).  After 15 min, 1, 6-
dibromohexane (30.2 ml, 195.55 mmol, 5 equiv) was added dropwise to the solution.  The 
reaction mixture was stirred at room temperature for 3 h.  The mixture was quenched with 
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water, diluted with EtOAc (600 ml), washed with brine (3x300 ml).  The EtOAc fraction was 
dried over anhydrous sodium sulfate and concentrated in vacuo.  The residue was purified by 
flash column chromatography (silica gel, 1-50% EtOAc/hexanes) to afford compound 26 
(11.076 g, 72% yield); 1H NMR (CD3OD, 600 MHz) δ 3.57 (t, 2H, J = 4.8 Hz), 3.54 (t, 2H, J 
= 5.4 Hz), 3.38 (t, 2H, J = 6.6 Hz), 3.34 (t, 2H, J = 5.4 Hz), 3.32-3.28 (m, 2H), 3.24-3.20 (m, 
2H), 1.83-1.76 (m, 2H), 1.55-1.47 (m, 2H), 1.45-1.38 (m, 2H), 1.40 (s, 9H), 1.30-1.22 (m, 
2H); 13C NMR (CD3OD, 150 MHz): δ 27.18, 28.95, 29.12, 29.57, 34.1, 34.5, 48.2, 48.4, 52.1, 
71.28, 71.59, 81.14, 157.55 ppm. HRMS (DART) m/z: calcd for C15H29BrN4O3 + H
+ 
393.1496; found 393.1500 (M + H)+. 
 
 
 
Methyl 3-((6-((2-(2-azidoethoxy)ethyl)(tert-butoxycarbonyl)amino)hexyl)oxy)-5-
hydroxybenzoate (27).  To a solution of 26 (11.0 g, 27.97 mmol, 1 equiv) and methyl 3,5-
dihydroxybenzoate (14.12 g, 83.90 mmol, 3 equiv) in anhydrous DFM (100 ml) was added 
K2CO3 (5.80 g, 41.96 mmol, 1.5 equiv).  The suspension was stirred at room temperature for 
16 h.  The suspension was quenched with water, diluted with EtOAc (500 ml), washed with 
brine (3x300 ml).  The EtOAc fraction was dried over anhydrous sodium sulfate and 
concentrated in vacuo.  The solution was concentrated under reduced pressure and the residue 
was purified by flash column chromatography (silica gel, 1-60% EtOAc/hexanes) to afford 
compound 27 (5.91 g, 44% yield); 1H NMR (CD3OD, 600 MHz) δ 6.95-6.93 (m, 2H), 6.49 (t, 
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1H, J = 2.4 Hz), 3.89 (t, 2H, J = 6.6 Hz), 3.79 (s, 3H), 3.55 (t, 2H, J = 4.8 Hz), 3.52 (t, 2H, J 
= 5.4 Hz), 3.32 (t, 2H, J = 5.4 Hz), 3.30-3.26 (m, 2H), 3.24-3.19 (m, 2H), 1.74-1.67 (m, 2H), 
1.56-1.48 (m, 2H), 1.47-1.41 (m, 2H), 1.38 (s, 9H), 1.32-1.25 (m, 2H); 13C NMR (CD3OD, 
150 MHz): δ 27.07, 27.74, 28.94, 29.67, 30.41, 48.20, 48.44, 52.06, 52.82, 69.26, 70.62, 
71.25, 81.16, 107.71, 107.92, 110.12, 133.26, 157.72, 160.07, 161.92, 168.72 ppm. HRMS 
(DART) m/z: calcd for C23H36N4O7 + H
+ 481.2657; found 481.2688 (M + H)+. 
 
 
 
Methyl 3-((6-((2-(2-azidoethoxy)ethyl)(tert-butoxycarbonyl)amino)hexyl)oxy)-5-
(3-bromopropoxy)benzoate (28).  To a solution of 27 (5.00 g, 10.4 mmol, 1 equiv) and 1,3-
dibromopropane (5.28 ml, 52 mmol, 5 equiv) in DMF (60 ml) was added K2CO3 (2.153 g, 
15.6 mmol, 1.5 equiv).  The suspension was stirred at room temperature overnight. The 
reaction was quenched with water, diluted with EtOAc (200 ml), and washed with brine 
(3x100 ml).  The EtOAc fraction was dried over anhydrous sodium sulfate and concentrated 
in vacuo.  The solution was concentrated under reduced pressure and the residue was purified 
by flash column chromatography (silica gel, 1-50% EtOAc/hexanes) to afford compound 28 
(5.43 g, 87% yield); 1H NMR (CD3OD, 600 MHz) δ 7.07 (d, 2H, J = 1.8 Hz), 6.65 (t, 1H, J = 
2.4 Hz), 4.06 (t, 2H, J  = 6 Hz), 3.93 (t, 2H, J  = 6 Hz), 3.81 (s, 3H), 3.58-3.54 (m, 4H), 3.52 
(t, 2H, J = 5.4 Hz), 3.32 (t, 2H, J  = 5.4 Hz), 3.30-3.26 (m, 2H), 3.24-3.19 (m, 2H), 2.25- 2.20 
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(m, 2H), 1.76-1.68 (m, 2H), 1.57-1.49 (m, 2H), 1.48-1.42 (m, 2H), 1.38 (s, 9H), 1.32-1.25 
(m, 2H); 13C NMR (CD3OD, 150 MHz): δ 27.07, 27.73, 28.94, 29.68, 30.38, 30.68, 33.69, 
49.73, 49.77, 52.07, 52.94, 67.13, 69.44, 70.76, 71.31, 81.16, 107.57, 108.78, 109.21, 133.39, 
157.72, 161.59, 161.91, 168.45. HRMS (DART) m/z: calcd for C26H41BrN4O7 + H
+ 
601.2232; found 601.2242 (M + H)+. 
 
 
 
Methyl 3-((6-((2-(2-azidoethoxy)ethyl)(tert-butoxycarbonyl)amino)hexyl)oxy)-5-
(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)benzoate (29).  To a solution of 28 (3.50 g, 5.82 
mmol, 1 equiv), in benzene (15 ml) was added dropwise a solution of acetyl acetone (1.195 
ml, 11.64 mmol, 2 equiv) and DBU (1.74 ml, 11.64 mmol, 2 equiv) in benzene (25 ml).  The 
reaction mixture was stirred at room temperature for 3 days.  The mixture was filtered and 
passed through a pad of silica gel.  The solvent was removed and the residue was dissolved in 
anhydrous ethanol (30 ml). Hydrazine hydrate (0.76 ml, 14.55 mmol, 2.5 equiv) was added 
and the reaction was heated under reflux for 4 h.  The reaction was concentrated and purified 
by flash column chromatography (silica gel, 1-100% EtOAc/hexanes) to afford compound 29 
(1.29 g, 36% yield); 1H NMR (CD3OD, 600 MHz) δ 7.05-7.02 (m, 2H), 6.60 (t, 1H, J = 2.4 
Hz), 3.90 (t, 2H, J  = 6 Hz), 3.84 (t, 2H, J  = 6 Hz), 3.81 (s, 3H), 3.56-3.52 (m, 2H), 3.51 (t, 
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2H, J = 5.4 Hz), 3.31 (t, 2H, J = 5.4 Hz), 3.28-3.25 (m, 2H), 3.23-3.19 (m, 2H), 2.5 (t, 2H, J 
= 7.2 Hz), 2.06 (s, 6H), 1.87-1.81 (m, 2H), 1.74-1.68 (m, 2H), 1.55-1.48 (m, 2H), 1.47-1.40 
(m, 2H), 1.38 (s, 9H), 1.31-1.24 (m, 2H); 13C NMR (CD3OD, 150 MHz): δ 19.89, 26.94, 
27.61, 28.81, 29.54, 30.25, 30.84, 48.10, 48.30, 51.92, 52.79, 67.93, 69.27, 70.81, 71.15, 
81.00, 107.32, 108.67,108.71, 115.26, 133.19, 143.48, 157.43, 161.63, 161.78, 168.36. 
HRMS (DART) m/z: calcd for C31H48N6O7 + H
+ 617.3658; found 617.3662 (M + H)+ 
 
 
 
3-((6-((2-(2-Azidoethoxy)ethyl)(tert-butoxycarbonyl)amino)hexyl)oxy)-5-(3-(3,5-
dimethyl-1H-pyrazol-4-yl)propoxy)benzoic acid (11).  To a solution of 29 (1.20 g, 1.95 
mmol, 1 equiv) in a mixture of MeOH (8 ml) and water (2 ml) was added NaOH (0.156 g, 3.9 
mmol, 2 equiv).  The reaction mixture was heated at 50oC for 14 h and then concentrated 
under reduced pressure.  The residue was extracted with 50% MeOH/EtOAc.  The combined 
organic extracts were concentrated under reduced pressure and the product was subject to 
purification by preparative HPLC to afford compound 11 (0.928 g, 79% yield); 1H NMR 
(CD3OD, 600 MHz) δ 7.04-7.01 (m, 2H), 6.56 (t, 1H, J = 2.4 Hz), 3.88 (t, 2H, J  = 6 Hz), 
3.82 (t, 2H, J  = 6 Hz), 3.53-3.5 (m, 2H), 3.49(t, 2H, J = 5.4 Hz), 3.29 (t, 2H, J = 5.4 Hz), 
3.26-3.22 (m, 2H), 3.18(t, 2H, J = 7.2), 2.48 (t, 2H, J = 7.2 Hz), 2.04 (s, 6H), 1.85-1.79 (m, 
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2H), 1.72-1.65 (m, 2H), 1.52-1.45 (m, 2H), 1.46-1.38 (m, 2H), 1.35 (s, 9H), 1.28-1.23 (m, 
2H); 13C NMR (CD3OD, 150 MHz): δ 10.75, 20.03, 27.08, 27.74, 28.95, 29.68, 30.41, 30.98, 
48.22, 48.43, 51.06, 68.02, 69.36, 70.77, 71.18, 81.16, 107.29, 109.03,109.71, 115.50, 
134.16, 143.50, 157.59, 161.70, 161.86, 169.9. HRMS (DART) m/z: calcd for C30H46N6O7 + 
H+ 603.3501; found 603.3510 (M + H)+.  
 
 
 
3-((6-((2-(2-azidoethoxy)ethyl)amino)hexyl)oxy)-5-(3-(3,5-dimethyl-1H-pyrazol-
4-yl)propoxy)benzoic acid (4).  To a solution of 11 (200 mg, 0.33 mmol, 1 equiv) was added 
a mixture containing TFA and CH2Cl2, (1:4 ratio) (5 mL).  The reaction was stirred at room 
temperature for 2 h.  The solution was concentrated under reduced pressure and purified by  
preparative HPLC to afford compound 4 (154 mg, 93% yield); (98% purity by HPLC): tR 
(column) (C18) = 22.2 min; tR (C4) = 18.2 min. 
1H NMR (CD3OD, 600 MHz)   7.02 (d, 2H, J 
= 2.4 Hz), 6.47 (t, 1H, J = 2.4), 3.89 (t, 2H, J = 6 Hz), 3.81 (t, 2H, J = 6 Hz), 3.69-3.65 (m, 
2H), 3.61-3.58 (m, 2H), 3.37-3.34 (m, 2H), 3.15-3.10 (m, 2H), 2.96-2.92 (m, 2H), 2.48 (t, 
2H, J = 7.2 Hz), 2.04 (s, 6H), 1.84-1.78 (m, 2H), 1.72-1.66 (m, 2H), 1.66-1.59 (m, 2H), 1.47-
1.41 (m, 2H), 1.40-1.33 (m, 2H); 13C NMR (CD3OD, 150 MHz): δ 10.76, 20.03, 26.84, 
27.26, 27.41, 30.12, 31.05, 48.91, 51.82, 67.16, 67.88, 69.06, 71.28, 71.65, 106.17, 108.82, 
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108.90, 115.45, 138.10, 143.48, 161.51, 169.37. HRMS (DART) m/z: calcd for C25H38N6O5 
+ H+ 503.2976; found 503.3004 (M + H)+. 
 
Chemical Synthesis of 3PEG-modified ligand 2 (compound 16) 
 
 
Scheme 5.  Synthesis of 3PEG-modified ligand 2 (compound 16).  a) NaH, 1,6-
dibromohexane, DMF, rt, 3 h; b) K2CO3, 3,5-dihydroxybenzoate, DMF, rt, 16 h; c) 
K2CO3,1,3-dibromopropane, DMF, rt, 16 h; d) i. acetylacetone, DBU, benzene, rt, 3 days; ii. 
hydrazine hydrate, ethanol, 90oC, 4 h; e) NaOH, MeOH/water, 50oC, 14 h. 
 
 
tert-Butyl (2-(2-(2-azidoethoxy)ethoxy)ethyl)(6-bromohexyl)carbamate (30).  To a 
solution of tert-Butyl 2-(2-azidoethoxy)ethoxyethylcarbamate (3.88 g, 14.14 mmol, 1 equiv) 
in anhydrous DMF (80 ml) was added NaH (1.13 g, 28.29 mmol, 2 equiv).  After 15 min, 1, 
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6-dibromohexane (11 ml, 71.24 mmol, 5.04 equiv) was added dropwise to the solution.  The 
reaction mixture was stirred at room temperature for 3 h.  The mixture was quenched with 
water, diluted with EtOAc (600 ml), washed with brine (3x300 ml). The EtOAc fraction was 
dried over anhydrous sodium sulfate and concentrated in vacuo.  The residue was purified by 
flash column chromatography (silica gel, 1-50% EtOAc/hexanes) to afford compound 30 
(4.690 g, 76% yield); 1H NMR (CD3OD, 600 MHz) δ 3.61-3.59 (m, 2H), 3.58-3.53 (m, 4H,), 
3.52 (t, 2H, J = 6Hz), 3.38 (t, 2H, J = 6.6 Hz), 3.32-3.28 (m, 4H), 3.19 (t, 2H, J = 6.6 Hz), 
1.82-1.75 (m, 2H), 1.54-1.45 (m, 2H), 1.44-1.38 (m, 2H), 1.38 (s, 9H), 1.28-1.21 (m, 2H); 
13C NMR (CD3OD, 150 MHz): δ 27.19, 28.95, 29.13, 29.6, 34.12, 34.5, 48.16, 48.32, 51.99, 
71.92, 71.40, 71.82, 81.12, 157.55 ppm. HRMS (DART) m/z: calcd for C17H33BrN4O4 + H
+ 
437.1758; found 437.1762 (M + H)+. 
 
 
 
Methyl 3-((6-((2-(2-(2-azidoethoxy)ethoxy)ethyl)(tert-butoxycarbonyl)amino)- 
hexyl)oxy)-5-hydroxybenzoate (31).  To a solution of 30 (4.56 g, 10.45 mmol, 1 equiv) and 
methyl 3,5-dihydroxybenzoate (5.27 g, 31.34 mmol, 3 equiv) in anhydrous DFM (80 ml) was 
added K2CO3 (2.16 mg, 15.63 mmol, 1.5 equiv).  The suspension was stirred at room 
temperature for 16 h.  The suspension was quenched with water, diluted with EtOAc (500 
ml), washed with brine (3x300 ml).  The EtOAc fraction was dried over anhydrous sodium 
sulfate and concentrated in vacuo.  The solution was concentrated under reduced pressure and 
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the residue was purified by flash column chromatography (silica gel, 1-5% MeOH/CH2Cl2) to 
afford compound 31 (1.91 g, 35% yield); 1H NMR (CD3OD, 600 MHz) δ 6.96-6.93 (m, 2H), 
6.49 (t, 1H, J = 2.4 Hz), 3.89 (t, 2H, J = 6.6 Hz), 3.79 (s, 3H), 3.59-3.57 (m, 2H), 3.57-3.53 
(m, 4H), 3.52 (t, 2H, J = 6 Hz), 3.31 (t, 2H, J = 6 Hz), 3.29-3.26 (m, 2H), 3.23-3.18 (m, 2H), 
1.74-1.68 (m, 2H), 1.56-1.48 (m, 2H), 1.47-1.41 (m, 2H), 1.38 (s, 9H), 1.32-1.25 (m, 2H); 
13C NMR (CD3OD, 150 MHz): δ 27.09, 27.74, 28.94, 29.46, 30.41, 48.12, 48.32, 51.97, 
52.82, 69.27, 70.92, 71.39,71.82, 81.13, 107.70, 107.92, 110.12, 133.27, 157.62, 160.08, 
161.92, 168.71 ppm. HRMS (DART) m/z: calcd for C25H40N4O8 + H
+ 525.2919; found 
525.2920 (M + H+). 
 
 
 
Methyl 3-((6-((2-(2-(2-azidoethoxy)ethoxy)ethyl)(tert-butoxycarbonyl)amino)- 
hexyl)oxy)-5-(3-bromopropoxy)benzoate (32).  To a solution of 31 (1.5 g, 2.87 mmol, 1 
equiv) and 1,3-dibromopropane (1.45ml, 14.3 mmol, 5 equiv) in DMF (20 ml) was added 
K2CO3 (0.594 g, 4.3 mmol, 1.5 equiv).  The suspension was stirred at room temperature for 
16 h. The reaction was quenched with water, diluted with EtOAc (300 ml), and washed with 
brine (3x200 ml).  The EtOAc fraction was dried over anhydrous sodium sulfate and 
concentrated in vacuo.  The solution was concentrated under reduced pressure and the residue 
was purified by flash column chromatography (silica gel, 1-50% EtOAc/hexanes) to afford 
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compound 32 (1.57 g, 85% yield); 1H NMR (CD3OD, 600 MHz) δ 7.07 (d, 2H, J = 2.4 Hz), 
6.65 (t, 1H, J = 2.4 Hz), 4.06 (t, 2H, J  = 6 Hz), 3.93 (t, 2H, J  = 6 Hz), 3.82 (s, 3H), 3.60-
3.57 (m, 2H), 3.56-3.54 (m, 6H), 3.52 (t, 2H, J = 6 Hz), 3.31 (t, 2H, J = 5.4 Hz), 3.28 (t, 2H, 
J = 4.8 Hz), 3.23-3.18 (m, 2H), 2.26- 2.20 (m, 2H), 1.76-1.69 (m, 2H), 1.58-1.49 (m, 2H), 
1.48-1.41 (m, 2H), 1.38 (s, 9H), 1.32-1.26 (m, 2H); 13C NMR (CD3OD, 150 MHz): δ 27.08, 
27.74, 28.96, 29.70, 30.39, 30.71, 33.68, 49.14, 48.32, 51.97, 52.95, 67.11, 69.43, 70.94, 
71.39,71.81, 81.11, 107.55, 108.77, 109.21, 133.37, 157.67, 161.56, 161.91, 168.43. HRMS 
(DART) m/z: calcd for C28H45BrN4O8 + H
+ 645.2494; found 645.2493 (M + H)+. 
 
 
 
Methyl 3-((6-((2-(2-(2-azidoethoxy)ethoxy)ethyl)(tert-butoxycarbonyl)amino)- 
hexyl)oxy)-5-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)benzoate (33).  To a solution of 
32 (1.22 g, 1.89 mmol, 1 equiv), in benzene (7 ml) was added dropwise a solution of acetyl 
acetone (0.388 ml, 3.78 mmol, 2 equiv) and DBU (0.564 ml, 3.78 mmol, 2 equiv) in benzene 
(13 ml).  The reaction mixture was stirred at room temperature for 3 days.  The mixture was 
filtered and passed through a pad of silica gel.  The solvent was removed and the residue was 
dissolved in anhydrous ethanol (10 ml). Hydrazine hydrate (0.232 ml, 4.73 mmol, 2.5 equiv) 
was added and the reaction was heated under reflux for 4 h.  The reaction was concentrated 
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and purified by flash column chromatography (silica gel, 1-20% MeOH/CH2Cl2) to afford 
compound 33 (413 mg, 33% yield); 1H NMR (CD3OD, 600 MHz) δ 7.05-7.02 (m, 2H), 6.60 
(t, 1H, J = 2.4 Hz), 3.91 (t, 2H, J  = 6 Hz), 3.84 (t, 2H, J  = 6 Hz), 3.81 (s, 3H), 3.59-3.57 (m, 
2H), 3.56-3.53 (m, 4H), 3.51 (t, 2H, J = 6 Hz), 3.30 (t, 2H, J = 5.4 Hz), 3.27 (t, 2H, J = 5.4 
Hz), 3.22-3.18 (m, 2H), 2.50 (t, 2H, J = 7.2 Hz), 2.06 (s, 6H), 1.87-1.82 (m, 2H), 1.74-1.68 
(m, 2H), 1.55-1.48 (m, 2H), 1.47-1.41 (m, 2H), 1.38 (s, 9H), 1.31-1.24 (m, 2H); 13C NMR 
(CD3OD, 150 MHz): δ 20.04, 27.10, 27.76, 28.96, 29.71, 30.41, 30.98, 48.15, 48.34, 51.97, 
52.94, 68.07, 69.41, 70.94, 71.39, 71.82, 81.11, 107.46, 108.8, 108.87, 115.40, 133.34, 
143.46, 157.60, 161.78, 161.92, 168.50. HRMS (DART) m/z: calcd for C33H52N6O8 + H
+ 
661.3920; found 661.3929 (M + H)+. 
 
 
 
3-((6-((2-(2-(2-azidoethoxy)ethoxy)ethyl)(tert-butoxycarbonyl)amino)hexyl)oxy)-
5-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)benzoic acid (16).  To a solution of 33 (400 
mg, 0.606 mmol, 1 equiv) in a mixture of MeOH (4 ml) and water (1 ml) was added NaOH 
(48.4 mg, 1.21 mmol, 2 equiv).  The reaction mixture was heated at 50oC for 14 h and then 
concentrated under reduced pressure.  The residue was extracted with 1% acetic acid in 50% 
MeOH/EtOAc.  The combined organic extracts were concentrated under reduced pressure 
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and the product was subject to purification by preparative HPLC to afford compound 16 (294 
mg, 75% yield); 1H NMR (CD3OD, 600 MHz) δ 7.05-7.01 (m, 2H), 6.56 (t, 1H, J  = 2.4 Hz), 
3.88 (t, 2H, J  = 6 Hz), 3.81 (t, 2H, J  = 6 Hz), 3.56-3.53 (m, 2H), 3.53-3.49 (m, 4H), 3.49-
3.46 (m, 2H), 3.27 (t, 2H, J = 5.4 Hz), 3.25-3.22 (m, 2H), 3.17 (t, 2H, J = 7.2 Hz), 2.48 (t, 
2H, J = 7.2 Hz), 2.04 (s, 6H), 1.85-1.79 (m, 2H), 1.72-1.65 (m, 2H), 1.52-1.44 (m, 2H), 1.44-
1.38 (m, 2H), 1.34 (s, 9H), 1.28-1.22 (m, 2H); 13C NMR (CD3OD, 150 MHz): δ 10.76, 20.04, 
27.11, 27.76, 28.96, 29.217, 30.42, 31.0, 48.15, 48.34, 51.97, 68.03, 69.37, 70.90, 71.39, 
71.82, 81.12, 107.27, 109.01, 109.08, 115.47, 134.23, 143.48, 157.61, 161.70, 161.86, 
169.94. HRMS (DART) m/z: calcd for C32H50N6O8 + H
+ 647.3763; found 647.3775 (M + 
H)+. 
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Scheme 6.  Synthesis of PSMA ligand 22 and intermediates 10 and 15. a) Fmoc-L-
propargylglycine, HOBt monohydrate, EDCI, DIPEA, DCM, rt, 16 h. b) DMF, piperidine 
(1:1), rt, 3 h. c) 20% TFA in DCM, rt, 3 h. d) 3-Tritylthio propionic acid, HOBt 
monohydrate, EDCI, DIPEA, DCM, rt, 16 h. 
 
84 
 
 
tri-tert-butyl 1-(9H-fluoren-9-yl)-3,6,13,21-tetraoxo-5-(prop-2-yn-1-yl)-2-oxa-
4,7,14,20,22-pentaazapentacosane-19,23,25-tricarboxylate (35).  To a solution of 34 
(synthesized as reported earlier)73 (9.4 g, 15.6 mmol, 1 equiv) in DCM (100 ml) was added 
Fmoc-L-propargylglycine (5.8 g, 17.16 mmol, 1.1 equiv), HOBt monhydrate (2.39 g, 15.6 
mmol, 1 equiv), EDCI (2.99 g, 15.6 mmol, 1 equiv), and DIPEA (7.73 ml, 46.8 mmol, 3 
equiv).  The reaction was flushed with nitrogen and stirred overnight.  The crude reaction 
mixture was then diluted with DCM (350 ml) and washed with water (3×100 ml).  The DCM 
fraction was concentrated under reduced pressure and the residue was purified by flash 
column chromatography (silica gel, 1-10% EtOAc/hexanes) to afford compound 35 (11 g, 
76% yield); 1H NMR (CD3OD, 600 MHz) δ 7.76 (d, 2H, J  = 7.8 Hz), 7.64 (d, 2H, J  = 7.8 
Hz), 7.36 (t, 2H, J  = 7.8 Hz), 7.28 (t, 2H, J  = 7.8 Hz), 4.39-4.29 (m, 2H), 4.23-4.10 (m, 4H), 
3.22-3.09 (m, 4H), 2.68-2.53 (m, 2H), 2.33-2.23 (m, 3H), 2.13 (t, 2H, J  = 7.8 Hz), 2.05-1.98 
(m, 1H), 1.80-1.70 (m, 2H), 1.62-1.26 (m, 11H), 1.45-1.41 (m, 27H); 13C NMR (CD3OD, 150 
MHz): δ 21.72, 22.63, 25.33, 26.13, 26.97, 27.00, 27.04, 27.72, 28.66, 28.70, 31.90, 35.67, 
38.75, 39.00, 47.04, 52.83, 53.50, 54.13, 66.80, 71.00, 79.09, 80.41, 81.25, 81.48, 119.63, 
124.91, 124.96, 126.86, 127.50, 141.27, 143.86, 143.91, 156.86, 158.60, 171.31, 172.17, 
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172.42, 172.61, 174.67. HRMS (DART) m/z: calcd for C50H71N5O11 + H
+ 918.5223; found 
918.5183 (M + H)+. 
 
 
tri-tert-butyl 21-amino-5,13,20-trioxo-4,6,12,19-tetraazatetracos-23-yne-1,3,7-
tricarboxylate (10).  To a solution of 35 (9 g, 9.8 mmol, 1 equiv) in DMF (40 ml), was 
added piperidine (40 ml) and the reaction was stirred at room temperature for 3 h.  The 
solution was concentrated under reduced pressure and the residue was purified by flash 
column chromatography (silica gel, 1-100% EtOAc/hexanes and then 5% MeOH/EtOAc) to 
afford compound 10 (5.93 g, 87% yield); 1H NMR (CD3OD, 600 MHz) δ 4.18-4.16 (m, 1H), 
4.12-4.09 (m, 1H), 3.84 (t, 1H, J  = 6 Hz), 3.27-3.16 (m, 2H), 3.14 (t, 2H, J  = 6 Hz), 2.78-
2.69 (m, 2H), 2.60 (t, 1H, J  = 2.4 Hz), 2.34-2.25 (m, 2H), 2.16 (t, 2H, J  = 7.2 Hz), 2.05-1.99 
(m, 1H), 1.81-1.71 (m, 2H), 1.63-1.30 (m, 11H), 1.46-1.42 (m, 27H). 13C NMR (CD3OD, 150 
MHz): δ 21.77, 22.66, 26.13, 26.95, 26.98, 27.01, 27.70, 28.60, 28.64, 31.15, 31.88, 35.58, 
38.75, 39.11, 52.01, 52.84, 53.52, 73.16, 76.66, 80.43, 81.26, 81.48, 158.62, 166.36, 168.36, 
172.15, 172.43, 172.61. HRMS (DART) m/z: calcd for C35H61N5O9 + H
+ 696.4542; found 
696.4552 (M + H)+. 
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21-amino-5,13,20-trioxo-4,6,12,19-tetraazatetracos-23-yne-1,3,7-tricarboxylic 
acid (22).  To a solution of 10 (50 mg, 0.072 mmol, 1 equiv) in DCM (3.2 ml) was added 
TFA (0.8 ml).  The reaction was stirred at room temperature for 3 h and then dried under 
vacuum.  The crude reaction mixture was then purified using preparative HPLC to afford 22 
(22.7 mg, 60% yield); (97% purity by HPLC): tR (column) (C18) = 10.1 min; tR (C4) = 5.4 
min.1H NMR (CD3OD, 600 MHz) δ 4.23-4.19 (m, 2H), 3.94 (t, 1H, J  = 6 Hz), 3.27-3.21 (m, 
2H), 3.15 (t, 2H, J  = 6 Hz), 2.81-2.73 (m, 2H), 2.60 (t, 1H, J = 2.4 Hz), 2.42-2.32 (m, 2H), 
2.16 (t, 2H, J  = 7.2 Hz), 2.13-2.07 (m, 1H), 1.92-1.78 (m, 2H), 1.66-1.47 (m, 7H), 1.42-1.31 
(m, 4H). 13C NMR (CD3OD, 150 MHz): δ 21.36, 22.60, 25.16, 25.91, 28.28, 28.46, 28.49, 
30.26, 32.25, 35.49, 38.75, 39.13, 51.81, 53.27, 53.37, 73.33, 76.43, 158.75, 165.75, 167.76, 
175.88, 175.98, 176.24. HRMS (DART) m/z: calcd for C23H37N5O9 + H
+ 528.2664; found 
528.2627 (M + H)+. 
 
87 
 
 
Tri-tert-butyl 5,8,15,23-tetraoxo-1,1,1-triphenyl-7-(prop-2-yn-1-yl)-2-thia-
6,9,16,22,24-pentaazaheptacosane-21,25,27-tricarboxylate (15).  To a solution of 10 (1 g, 
1.44 mmol, 1 equiv) in DCM (20 ml) was added 3-Tritylthio propionic acid (502 mg, 1.44 
mmol, 1 equiv), HOBt monhydrate (220 mg, 1.44 mmol, 1 equiv), EDCI (276 mg, 1.44 
mmol, 1 equiv), and DIPEA (0.71 ml, 4.32 mmol, 3 equiv). The reaction was flushed with 
nitrogen and stirred for 16 h.  The crude reaction mixture was then diluted with DCM (150 
ml) and washed with water (3×100 ml).  The DCM fraction was dried over anhydrous sodium 
sulfate, filtered, and concentrated under reduced pressure.  The residue was purified by flash 
column chromatography (silica gel, 1-10% EtOAc/hexanes) to afford compound 15 (1.02 g, 
69% yield).  1H NMR (CD3OD, 600 MHz) δ 7.37-7.35 (m, 6H), 7.27 (t, 6H, J  = 7.8 Hz), 
7.19 (t, 3H, J  = 7.8 Hz), 4.39 (t, 1H, J  = 7.2 Hz), 4.19-4.16 (m, 1H), 4.12-4.10 (m, 1H), 
3.15-3.07 (m, 4H), 2.64-2.51 (m, 2H), 2.46-2.39 (m, 2H), 2.32-2.27 (m, 3H), 2.23 (t, 2H, J  = 
7.2 Hz), 2.12 (t, 2H, J  = 7.2 Hz), 2.04-1.99 (m, 1H), 1.81-1.71 (m, 2H), 1.63-1.30 (m, 11H), 
1.46-1.42 (m, 27H); 13C NMR (CD3OD, 150 MHz): δ 21.30, 22.64, 25.32, 26.11, 26.97, 
27.00, 27.03, 27.65, 27.71, 28.70, 31.16, 31.89, 34.28, 35.69, 37.38, 38.76, 38.96, 52.42, 
52.83, 53.50, 66.51, 71.01, 78.96, 80.42, 81.25, 81.47, 126.53, 127.64, 129.40, 144.80, 
158.61, 162.42, 170.77, 172.16, 172.42, 172.55, 174.67. HRMS (DART) m/z: calcd for 
C57H79N5O10S + H
+ 1026.5621; found 1026.5503 (M + H)+. 
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Scheme 7.  Synthesis of TFM1 (5). a) CuSO4, sodium ascorbate, of H2O/THF (2:1), rt, 3 h; b)  
Sulfo-Cyanine7 NHS ester, DIPEA, DMF, rt, 16 h; c) TFA, TIS, and CH2Cl2 (50:3:100 
ratio), rt, 2 h. 
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Synthesis of 25.  The click (CuAAC) was carried out by reacting 10 (150 mg, 0.216 
mmol, 1 equiv) with 11 (130 mg, 0.216 mmol, 1 equiv), and CuSO4 pentahydrate (14 mg, 
0.054 mmol, 0.25 equiv), and sodium ascorbate (21 mg, 0.108 mmol, 0.5 equiv) in a mixture 
of H2O/THF (2:1) (3 ml).  The reaction mixture was stirred at room temperature overnight.   
The solution was concentrated under reduced pressure.  The residue was extracted with 10% 
MeOH/EtOAc.  The combined organic extracts were concentrated under reduced pressure 
and purified by preparative HPLC to afford compound 12 (129 mg, 46% yield). ESI-MS: 
Exact mas calcd for C65H107N11O16 [M+H]
+ 1298.8; [M+Na]+ 1320.8; [M+2H]2+ 649.9; 
[M+H+Na]2+ 660.9. Found: 1299.0, 1321.1, 650.2, 661.3] 
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Synthesis of 13.  To a solution of 12 (50 mg, 0.039 mmol, 1 equiv) and the amine 
reactive succinimide ester (sulfo-Cyanine7) [sodium 1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-
oxohexyl)-3,3-dimethyl-2-((E)-2-((Z)-3-((Z)-2-(1,3,3-trimethyl-5-sulfonatoindolin-2-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3H-indol-1-ium-5-sulfonate] (32 mg, 0.039 
mmol, 1 equiv) in anhydrous DMF (3 ml), was added DIPEA (0.064 ml, 0.39 mmol, 10 
equiv).  The reaction mixture was stirred at room temperature for 16 h.  The solution was 
concentrated under reduced pressure and purified by preparative HPLC to afford compound 
13 (48 mg, 62% yield); Exact mas calcd for C102H149N13O23S2 [M+H]
+ 1989.0; [M+Na]+ 
2011.0 [M+2H]2+ 995.0. Found: 1989.3, 2011.4, 996.0. 
 
 
  
Synthesis of TFM1 (5).  To a solution of 13 (20 mg, 0.010 mmol, 1 equiv) was added 
a mixture containing TFA and CH2Cl2, (1:9 ratio) (2 ml) and the reaction was stirred at room 
temperature for 3 h.  The solution was concentrated under reduced pressure and purified by 
preparative HPLC to afford compound TFM1 (5) (15 mg, 87% yield); (97% purity by 
HPLC): tR (column) (C18) = 19 min; tR (C4) = 14.5 min (Figure 26); ESI-MS: Exact mas 
calcd for C85H117N13O21S2 [M+H]
+ 1720.8; [M+Na]+ 1742.8; [M+H]2+ 860.9; [M+H+Na]2+ 
91 
871.9; [M+2Na-H]+ 1764.8. Found: 1721.3, 1743.3, 861.5, 872.6, 1765.4.  (Data generated 
by: Wabel Albusairi)  
 
 
Figure 26.  HPLC chromatogram of pure TFM1 in C18 and in C4 column. 
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Scheme 8.  Synthesis of BFM1 (8).  a) Sulfo-Cyanine7 NHS ester, DIPEA, DMF, rt, 16 h; b) 
TFA, TIS, and CH2Cl2 (50:3:100 ratio), rt, 2 h. 
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Synthesis of 14.  To a solution of 10 (30 mg, 0.043 mmol, 1 equiv) and the amine 
reactive succinimide ester (sulfo-Cyanine7) (36 mg, 0.0043 mmol, 1 equiv) in anhydrous 
DMF (3 ml), was added DIPEA (0.075 ml, 0.43 mmol, 10 equiv).  The reaction mixture was 
stirred at room temperature for 16 h. The solution was concentrated under reduced pressure 
and purified by preparative HPLC to afford compound 14 (33 mg, 55% yield); Exact mas 
calcd for C72H103N7O16S2 [M+H]
+ 1386.7; [M+Na]+ 1408.7; [M+2H]2+ 693.9; [M+H+Na]2+; 
704.3. Found: 1387.0, 1409.0, 694.1, 705.2. 
 
94 
 
 
Synthesis of BFM1 (8).  To a solution of 14 (20 mg, 0.014 mmol, 1 equiv) was added 
a mixture of TFA and CH2Cl2, (1:9 ratio) (2 ml) and the reaction was stirred at room 
temperature for 3 h.  The solution was concentrated under reduced pressure and purified by 
preparative HPLC to afford compound BFM1 (8) (14 mg, 81% yield); (95% purity by 
HPLC): tR (column) (C18) = 21 min; tR (C4) = 16.7 min (Figure 27); ESI-MS: Exact mas 
calcd for C60H79N7O16S2 [M+H]
+ 1218.5. Found: 1218.7.   
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Figure 27.  HPLC chromatogram of pure BFM1 in C18 and in C4 column. 
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Scheme 9.  Synthesis of TFM2 (6). a) CuSO4, sodium ascorbate, of H2O/THF (2:1), rt, 3 h; b) 
TFA, TIS and CH2Cl2 (10: 10: 1 ratio); c) VcMMAE, TEA, DMF, rt, 5 h. 
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Synthesis of 17.   The click (CuAAC) coupling was carried out by reacting 15 (103 
mg, 0.1 mmol, 1 equiv), 11 (60 mg, 0.1 mmol, 1 equiv), CuSO4 (6.1 mg, 0.025 mmol, 0.25 
equiv), and sodium ascorbate (16 mg, 0.05 mmol, 0.5 equiv) in a mixture of H2O/THF (2:1) 
(3 ml).  The reaction mixture was stirred at room temperature for 3 h. The solution was 
concentrated under reduced pressure.  The residue was extracted with 20% MeOH/EtOAc.  
The combined organic extracts were concentrated under reduced pressure and purified by 
flash column chromatography (silica gel, 1-40% MeOH/EtOAc) to afford compound 17 (75 
mg, 46% yield). ESI-MS: Exact mas calcd for C87H125N11O17S [M+H]
+ 1628.9 [M+Na]+ 
1650.9; [M+2H]2+ 815.0. Found: 1628.0, 1651.8, 815.2. 
 
 
 
Synthesis of 19.  To a solution of 17 (33 mg, 0.02 mmol, 1 equiv), a mixture of TFA, 
TIS, and CH2Cl2 (10: 10: 1 ratio) (2 ml) was added and the reaction was stirred at room 
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temperature for 2 h.  The solution was concentrated under reduced pressure. The residue was 
washed with CH2Cl2 (3x10 ml), and extracted with 20% MeOH/EtOAc.  The combined 
organic extracts were concentrated under reduced pressure and purified by preparative HPLC 
to afford compound 19; (20 mg, 88% yield).  ESI-MS: Exact mas calcd for C51H79N11O15S 
[M+H]+ 1118.6; [M+2H]2+ 559.8. Found: 1117.8, 559.5. 
 
 
Synthesis of TFM2 (6).  The maleimide-thiol conjugation reaction was carried out by 
reacting 19 (17 mg, 0.015 mmol, 1 equiv) with VcMMAE (14 mg, 0.01 mmol, 0.7 equiv) and 
TEA (50 μl) in anhydrous DMF (1.5 ml). The reaction mixture was stirred at room 
temperature for 5 h.  The solution was concentrated under reduced pressure.  The residue was 
washed with CH2Cl2 (3x10 ml) to remove any unreacted VcMMAE.  The residue was 
extracted with 20% MeOH/CH2Cl2.  The combined organic extracts were concentrated under 
reduced pressure and purified by preparative HPLC to afford TFM2 (6) (11 mg, 31% yield); 
(95% purity by HPLC): tR (column) (C18) = 27.7 min; tR (C4) = 12.0 min (Figure 28); ESI-
MS: Exact mas calcd for C119H185N22O30S [M+2H]
2+ 1218.2; [M+3H]3+ 812.5; [M+2H+Na]3+ 
819.8. Found: 1218.0, 812.5, 819.9.  
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Figure 28.  HPLC chromatogram of pure TFM2 in C18 and in C4 column. 
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Scheme 10.  Synthesis of TFM3 (7).  a) CuSO4, sodium ascorbate, of H2O/THF (2:1), rt, 3 h; 
b) TFA, TIS and CH2Cl2 (10: 10: 1 ratio); c) VcMMAE, TEA, DMF, rt, 5 h. 
101 
 
 
Synthesis of 18.  The click (CuAAC) coupling was carried out by reacting 15 (167 
mg, 0.163 mmol, 1 equiv), 16 (105 mg, 0.163 mmol, 1 equiv), CuSO4 (10 mg, 0.041 mmol, 
0.25 equiv), and sodium ascorbate (16 mg, 0.082 mmol, 0.5 equiv) in a mixture of H2O/THF 
(2:1) (3 ml).  The reaction mixture was stirred at room temperature for 3 h.  The solution was 
concentrated under reduced pressure. The residue was extracted with 20% MeOH/EtOAc.  
The combined organic extracts were concentrated under reduced pressure and purified by 
flash column chromatography (silica gel, 1-40% MeOH/EtOAc) to afford compound 18 (109 
mg, 40% yield).  ESI-MS: Exact mas calcd for C89H129N11O18S [M+H]
+ 1672.9; [M+Na]+ 
1694.9; [M+H+Na]2+ 848.0. Found: 1673.3, 1695.4, 848.4]. 
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Synthesis of 20.  To a solution of 18 (50 mg, 0.030 mmol, 1 equiv) a mixture of TFA, 
TIS, and CH2Cl2 (10: 10: 1 ratio) (2 ml) was added and the reaction was stirred at room 
temperature for 2 h.  The solution was concentrated under reduced pressure. The residue was 
washed with CH2Cl2 (3x10 ml), and extracted with 20% MeOH/EtOAc.  The combined 
organic extracts were concentrated under reduced pressure and purified by preparative HPLC 
to afford compound 20; (32 mg, 92% yield). ESI-MS: Exact mas calcd for C53H83N11O16S 
[M+H]+ 1162.6; [M+Na]+ 1184.6; [M+2H]2+ 581.8; [M+H+Na]2+ 592.8. Found: 1162.4, 
1183.9, 581.6, 592.3]. 
 
 
 
 
Synthesis of TFM3 (7).  The maleimide-thiol conjugation reaction was carried out by 
reacting 20 (31.3 mg, 0.027 mmol, 1 equiv) with VcMMAE (25 mg, 0.019 mmol, 0.7 equiv) 
and TEA (100 μl) in anhydrous DMF (3 ml). The reaction mixture was stirred at room 
temperature for 5 h.  The solution was concentrated under reduced pressure.  The residue was 
washed with CH2Cl2 (3x10 ml) to remove any unreacted VcMMAE.  The residue was 
extracted with 20% MeOH/CH2Cl2.  The combined organic extracts were concentrated under 
reduced pressure and purified by preparative HPLC to afford TFM3 (7) (17 mg, 36% yield); 
(97% purity by HPLC): tR (column) (C18) = 26.9 min; tR (C4) = 11.3 min (Figure 29); ESI-
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MS: Exact mas calcd for C121H188N22O31S [M+H]
+ 2478.4; [M+H]2+ 1239.7; [M+H]3+ 826.8. 
Found: 2478.7, 1240.8, 827.9].  (Data generated by: Wabel Albusairi) 
 
Figure 29.  HPLC chromatogram of pure TFM3 in C18 and in C4 column. 
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Scheme 11.  Synthesis of BFM2 (9).  a) TFA, TIS and CH2Cl2 (50:3:100 ratio); b) VcMMAE, 
TEA, DMF, rt, 5 h. 
 
 
 
 
105 
 
 
Synthesis of 21.  To compound 15 (110 mg, 0.107 mmol, 1 equiv) was added a 
mixture containing TFA, TIS, and CH2Cl2 (50:3:100 ratio) (3 ml).  The reaction was stirred at 
room temperature for 2 h and the solution was concentrated under reduced pressure.  The 
residue was washed with CH2Cl2 (3x10 ml) and extracted with 25% MeOH/EtOAc.  The 
combined organic extracts were concentrated under reduced pressure to afford compound 21 
(60 mg, 91% yield); which was used directly in the next step. ESI-MS: Exact mas calcd for 
C26H41N5O10S [M+H]
+ 616.26; [M+Na]+ 638.24. Found: 616.5, 638.4]. 
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Synthesis of BFM2 (9).  To a solution of 21 (45 mg, 0.073 mmol, 1 equiv) and 
VcMMAE (27 mg, 0.0205 mmol, 0.28 equiv) in anhydrous DMF (3 ml), was added 
triethylamine (0.1 ml).  The reaction mixture was stirred at room temperature for 5 h. The 
solution was concentrated under reduced pressure.  The residue was washed with CH2Cl2 
(3x10 ml) and then extracted with 20% MeOH/CH2Cl2.  The combined organic extracts were 
concentrated under reduced pressure and purified by preparative HPLC to afford compound 
BFM2 (9) (26 mg, 66% yield); (95% purity by HPLC): tR (column) (C18) = 27.2 min; tR (C4) 
= 13.0 min (Figure 30); ESI-MS: Exact mas calcd for C94H146N16O25S [M+H]
+ 1932.04; 
[M+Na]+ 1954.03; [M+2H]+ 966.56. [Found: 1932.5, 1954.5, 966.9].  (Data generated by: 
Wabel Albusairi) 
 
 
Figure 30.  HPLC chromatogram of pure BFM2 in C18 and in C4 column. 
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7.2.2.  In Silico Modeling Studies 
The geometry optimization of the ligand 2, 3, 4, and TFM3  was carried out at the 
hybrid density functional B3LYP level74 with 6-31G(d)75, 76 basis set using Gaussian’0977 
program package.  To confirm the optimized geometry is at minimum, frequency calculations 
were carried out on the optimized geometries. The docking experiments were carried out 
using Dock678.  The crystal structure of TTR (pdb id: 4HIQ)22 and the PSMA (pdb id: 
2XEF)59 were obtained from RCSB.org. UCSF Chimer program79 was used to analyze and 
visualize the proteins and docking complex structures. Due to the large size of TFM3, smaller 
versions of the ligands were prepared for the docking.  After docking PSMA and TTR with 
TFM3, the best protein-ligand docking complex was identified for each protein and they were 
superimposed onto the full TFM3 anchoring both ligand 2 and 22 conjugated to vcMMAE.   
7.2.3.  Biological In Vitro and In Vivo studies 
Evaluation of the aqueous solubility of test compounds.  The aqueous solubility of 
BFMs and TFMs was evaluated (at 200 µM) in Phosphate buffer saline (PBS, pH 7.4) as 
reported earlier80.  The samples were incubated at room temperature (25ºC) for 16 hours with 
moderate shaking (250 rpm).  The samples were then centrifuged (2500 rpm for 3 min) and 
filtered.  The concentration of test compounds in the filtrate was determined by HPLC 
(Figure 31).  External standard from the same batch of test compounds was used to generate 
calibration curves.  Each experiment was performed in duplicate.  All BFMs and TFMs 
displayed excellent solubility (at least 200 µM) as shown below (Figure 31). 
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Figure 31.  HPLC standard curves for determining aqueous solubility of TFMs and BFMs 
(tested at 200 µM) in PBS (pH 7.4) 
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Evaluation of Binding Affinity of Ligands to TTR in Buffer.  The affinity of 2, 3, 4 
and TFM1-3 to TTR was determined by their ability to displace FP probe from TTR using 
previously reported Fluorescence Polarization (FP) assay55. Serial dilutions of 2, 3, 4, and 
TFM1-3 (0.010 µM to 20 µM) were added to a solution of FP-probe (50 nM) and TTR (300 
nM) in assay buffer (PBS pH 7.4, 0.01% Triton-X100, 1% DMSO in 25 μl final volumes) in 
384-well plate.  The samples were allowed to equilibrate by agitation on a plate shaker for 20 
min at room temperature. Fluorescence polarization (excitation λ 485 nm, emission λ 525 nm, 
Cutoff λ 515 nm) measurements were taken using a SpectraMax M5 Microplate Reader 
(Molecular Devices).  The IC50 values were obtained by fitting the data to the following 
equation [y=(A-D)/(1+(x/C)^B) + D], where A=maximum FP signal, B=slope, C= apparent 
binding constant (Kapp), and D= minimum FP signal. The binding constant (Kd) values were 
calculated using the Cheng–Prusoff equation from the IC50 values.  All reported data 
represent the mean ± s.d. (n=3). 
Evaluation of Binding Affinity and Selectivity of Ligands to TTR in Human 
Serum.  The binding affinity and selectivity of ligands 2, 3, 4, and TFM1-3 to TTR was 
determined by their ability to compete with the binding of a fluorescent probe exclusion (FPE 
probe) binding to TTR in human serum as previously reported56, 57.  AG10 and Tafamidis 
were used as controls.  An aliquot (98 µl) of human serum was mixed with 1 μl of test 
compounds (1.0 mM stock solution in DMSO; 10 µM final concentration in serum) and 1 μl 
of FPE probe (0.36 mM stock solution in DMSO; 3.6 µM final concentration in serum).  The 
fluorescence changes (λex = 328 nm and λem = 384 nm) were monitored every 15 min using a 
SpectraMax M5 microplate reader for 6 h at 25oC.  
PSMA Enzyme Inhibition Assay for Evaluating the Preferential Binding of 
TFM1-3 for PSMA over TTR.  Test compounds (TFM1-3 and BFM1-2) were assayed for 
their ability to inhibit PSMA-catalyzed hydrolysis of N-acetylaspartylglutamate (NAAG) to 
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glutamate and N-acetylaspartate (NAA) in the PSMA enzyme inhibition assay using the 
Amplex® Red Glutamic Acid/Glutamate Oxidase Assay Kit.  PMPA and ligand 22 were 
used as positive controls.  A 10 mM solution of N-acetylaspartylglutamate (NAAG; MP 
Biomedicals, ICN15303625) in 40 mM NaOH was diluted to 40 μM in reaction buffer (0.1 M 
Tris·HCl, pH 7.5), and the solution was added to a 384-well plate (10 μl per well).  To 
measure PSMA/NAAG Km, the NAAG solution was serially diluted (2x) to obtain final 
NAAG concentrations ranging from 390 nM to 100 μM (prepared from the 10 mM stock).  
For IC50 measurements, the inhibitors in reaction buffer containing 40 μM NAAG solution 
were serially diluted (4x with buffer containing 40 μM NAAG) to obtain final inhibitor 
concentrations ranging from 1.5 nM to 100 μM.  To evaluate the ligands ability to inhibit 
PSMA in the presence of transthyretin, TTR was also added (at 1 μM final concentration) to 
the test compounds.  To initiate reactions, rhPSMA (20 μM in reaction buffer), was added to 
each well to a final concentration of 60 ng/ml.  The plate was incubated at 37°C for 30 min 
and then was heated to 90°C for 1 min.  After cooling, Amplex reaction mixture was added at 
a 1:1 volumetric ratio and incubated at 37°C for 1 h.  Fluorescence intensities were measured 
using a SpectraMax M5 microplate reader with excitation and emission filters of 545 and 590 
nm, respectively.  Ki values were calculated using the Cheng–Prusoff equation from IC50 and 
Km values (calculated using GraphPad Prism 8 software).  All reported data represent the 
mean ± s.d. (n=3). 
In Vitro Analysis of the Efficacy of MMAE Release Following Cathepsin B 
Cleavage.  Cathepsin B, extracted from human liver, was obtained frozen at 15.5 μM in 20 
mM sodium acetate and 1 mM EDTA at pH 5.0.  The enzyme was incubated with 25 mM 
sodium acetate, 1 mM EDTA, and 9.2 mM DTT at pH 5.5 for 15 min at ambient temperature 
for activation.  In the MMAE release assay, the activated cathepsin B at a final concentration 
of 100 nM was mixed with free MMAE, BFM2, TFM2 and TFM3 at a final concentration of 
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20 μM in the reaction buffer (25 mM sodium acetate and 1 mM EDTA at pH 5.5) at 37oC.   
Sample aliquots were taken at 0, 15 min, 30 min, 1 h and 2 h. Each aliquot of sample was 
immediately quenched by adding HPLC solvent (acetonitrile-water; 95:5 v/v, 0.1% formic 
acid), mixed by vortexing, placed at -20oC for 5 min, centrifuged at 15,000 RPM for 5 min 
and the supernatant was analyzed by HPLC (gradient method increasing linearly from 0-100 
% solvent B in 20 min) for quantifying the release of free MMAE.  HPLC detection was 
performed at 210 nm UV absorbance because of the low absorbance of MMAE at 254 nm.  
The identity of MMAE was also confirmed by LC-MS/MS. 
Evaluating the Effect of TTR on the Cytotoxicity of TFMs Against Prostate 
Cancer Cells.  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
was performed using CellTiter 96 Non-Radioactive Cell Proliferation Assay to determine cell 
viability.  LNCaP (PSMA+), DU145 (PSMA-), and HeLa  cells were cultured in RPMI-1640 
Medium   supplemented  with  10%  fetal  bovine  serum, penicillin/streptomycin (100 
unit/ml and 100µg/ml respectively) and 1% L-Glutamine under the humidified atmosphere of 
5% CO2 and 95% air at 37°C. The cells were grown to confluence, trypsinized and seeded 
into 96-well plates at a density of ~5,000 cells/well.  The cells were then treated with BFM2, 
TFM2, TFM3 (each at 0.001 nM to 100000 nM) or MMAE (0.001 nM to 1000 nM) as 
positive control in absence and presence of TTR (1 µM, 30 min preincubation with test 
compounds).  Control cells were also treated with the appropriate concentration of vehicle 
(DMSO) in absence and presence of TTR (1 µM, 30 min preincubation).  After 72 h 
incubation at 37°C, cell viability was determined following the standard CellTiter 96 Non-
Radioactive Cell Proliferation Assay protocol.  
Serum Stability Assay of TFM3 and BFM2.  TFM3 and BFM2 (50 μM) was 
incubated in PBS, human serum, or rat serum at 37°C and samples (50 μl) were assayed at 0 
h, 12 h, and 24 h time intervals. For the mouse serum, additional time points were included in 
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the study.  Samples were processed by adding 200 μl of solvent B (95% methanol and 0.1% 
Formic acid in water) followed by centrifuging at 15,000 rpm for 5 min (2x) and the 
supernatant was analyzed using HPLC.  HPLC analysis was performed on a Waters 
Symmetry300 C4 column (2.1 mm × 150 mm, 5 μm) using a gradient method increasing 
linearly from 0-100% solvent B in 20 min.  The mobile phase was composed of solvent A 
consisting of acetonitrile-water (5:95, v/v) containing 0.1% formic acid and solvent B 
consisting acetonitrile-water (95:5, v/v) containing 0.1% formic acid, at a flow rate of 0.5 
ml/minute.  The stability analysis of TFM3 and BFM2 (each at 5 μM) in mice serum was 
performed in the absence and presence of AG10 (10 μM) using the same procedure described 
above (using LC-MS/MS for analysis) to evaluate the protective effect of TTR on these 
molecules. 
Evaluating the Effect of TFM3 on holo-RBP-TTR Interaction in Serum.  A 
solution of thyroxine (T4), ligand 2, and TFM3 (1 μl of 2 mM stock solution in DMSO) or 
control (1 μl DMSO) was added (final compound concentrations 20 μM) to 99 μl of human 
serum (from human male AB plasma, Sigma; TTR concentration ~5 µM).  The treated serum 
was incubated at 37°C for 2 h.  After the incubation, all samples were analyzed using western 
blot using a procedure reported earlier23.  In this assay, 10 μl of the serum incubated with test 
compounds was added to 90 μl of buffer A (pH 7.0 PBS, 100 mM KCl, 1 mM EDTA, 1 mM 
DTT).  For the urea sample, 10 μl of the control serum (incubated with DMSO) was added to 
90 μl of urea buffer (buffer A containing 8 M urea).  All serum samples were then cross-
linked with glutaraldehyde (final concentration of 2.5%) for 5 min, and then quenched with 
10 μl of 7% sodium borohydride solution in 0.1 M NaOH.  The samples were denatured by 
adding 100 μl SDS gel loading buffer and boiled for 5 min. 10 μl of each sample was 
separated in 16% SDS-PAGE gels.  The gel was transferred using wet transfer (Bio-Rad; 
buffer: 3.03 g of Tris, 14.4 g of glycine, 200 ml methanol, 800 ml water).  Membrane was 
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blocked in blocking buffer (Sea-block blocking buffer, Fisher) for 30 min at room 
temperature.  The membrane was then incubated in anti-RBP antiserum at 1:500 dilution 
overnight at 4°C.  After incubation, the membrane was washed 4 times for 5 min each in 
0.1% Tween-20 PBS at room temperature.  Then, the membrane was incubated in IRdye800 
donkey anti-rabbit secondary antibody at 1:15,000 dilution in blocking buffer for 2 h at room 
temperature.  After incubation, the membrane was washed in similar manner as above and 
scanned using a LI-COR Odyssey® CLx Imaging System for quantification.  The free RBP 
band (at ~21 kDa) was quantified easily since it was well separated from the RBP-TTR 
complex (at ~77 kDa) which is also detected by the anti-RBP antiserum. 
Experimental Animals.  All rats and mice animal studies and euthanasia were 
conducted in accordance with National Institutes of Health guidelines for the care and use of 
live animals and were approved by the Institutional Animal Care and Use Committee at 
University of the Pacific. 
HPLC Analysis of Serum or Plasma Samples.  Analysis was performed on Agilent 
1100 system or Waters Alliance e2695 system attached to Water 2998 PDA detector 
operating between the UV ranges of 200 nm and 800 nm and quantified using Chemstation 
and Empower 3 software, respectively.  HPLC analysis was performed on a Waters XBridge 
C18 column (4.6 mm × 250 mm, 5 μm) and Waters Symmetry300 C4 column (2.1 mm × 150 
mm, 5 μm) at ambient temperature upon injection of a 50 μl of each standard and/or sample 
to obtain the chromatogram.  
Evaluation of the Pharmacokinetic Profile of BFM1, TFM1, BFM2, and TFM3 
in Rats.  Jugular vein cannulated male Wistar rats (200–220 g; 6-7 weeks old) were used for 
this study.  Animals were randomized in four treatment groups (n = 3 animals per group for 
BFM1 and TFM1; n = 4 animals per group for BFM2 and TFM3).  Each animal received one 
intravenous dose of either BFM1 (0.1 μmol/kg), TFM1 (0.1 μmol/kg), BFM2 (0.32 μmol/kg) 
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or TFM3 (0.16 μmol/kg), in 200µl saline through the jugular vein cannula.  Blood samples 
were collected from each rat, via jugular vein cannula, in heparinized tubes at predetermined 
time points (0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h post-dosing) and the volume was 
replaced with sterile normal saline.  The plasma samples were prepared by centrifugation at 
7,500 RPM for 15 min at 4oC, and stored at -80oC until further analysis.  For BFM1 and 
TFM1, the plasma samples were diluted with PBS in a black 96-well microplate with a clear 
bottom.  LI-COR Odyssey® CLx Imaging System was used to quantitate the concentration of 
BFM1, and TFM1 in rat plasma.  The fluorescence intensity of each compound was 
determined in the 800 nm channel.  The integrated intensity automatically quantified by LI-
COR Odyssey® CLx Imaging System, for each sampling time point, was converted to nM 
concentration by the calibration curves produced from the calibration samples of each 
compound. For BFM2 and TFM3, to each of the plasma samples of the standard curve, 2x 
volume of 100% acetonitrile was added to precipitate the proteins in the rat plasma.  The 
samples were vortexed for 30 seconds then placed on a mechanical shaker for 10 min at 
medium speed.  The samples were then centrifuged at 15,000 RPM for 10 min; the 
supernatant was collected and centrifuged again at 15,000 RPM for another 10 min.  
Subsequently, the supernatant was analyzed using validated LC/MS/MS method (using Triple 
Quadrupole mass spectrometer; AB SCIEX API-3000) to quantitate the concentration of 
BFM2 and TFM3 in plasma samples.  Fragmentation pattern and peak areas were used to 
identify and quantitate the test compounds respectively.  Based on a calibration curve for 
these compounds in rat plasma and the internal standard generated by the LC-MS/MS 
Analyst®, the concentrations in the plasma samples were then plotted as their natural 
logarithms against time.  A two-compartment model (using WinNonlin®) was used to obtain 
all the pharmacokinetic parameters.  Mean (± s.d.) concentrations of BFM1, TFM1, BFM2, 
and TFM3 in the plasma samples were plotted as their natural logarithms against time (h).  A 
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two-compartment model (using Phoenix WinNonlin) was used to obtain all the 
pharmacokinetic parameters for test compounds from their plasma concentration-time data. 
In Vivo Toxicity Study in Mice.  5-week-old CD-1 male mice (Charles River) were 
randomized into groups (n=4) with similar mean body weight.  The mice received either 
vehicle (5% Ethanol, 10% PEG 400 and 85% sterile water), TFM3 (300 nmol/kg and 600 
nmol/kg), BFM2 (300 nmol/kg and 600 nmol/kg), or MMAE (300 nmol/kg) via 
intraperitoneal injection (i.p.), every three days, total 4 doses.  Body weight and food and 
water intake were recorded every three days for 12 days.  Body weight changes from the 
beginning of treatment for the animals were calculated as mean (± s.d.) % change from day 0 
for each group. 
Xenograft Tumor Model Generation.  LNCaP (PSMA+) and DU145 (PSMA-) cells 
(PCa cells) were cultured in RPMI-1640 Medium supplemented with 10% fetal bovine 
serum, penicillin/streptomycin (100 unit/ml and 100 µg/ml respectively) and 1% L-
Glutamine under the humidified atmosphere of 5% CO2 and 95% air at 37°C.  The cells were 
grown to confluence, trypsinized and washed twice with cold HBSS (4°C) and collected by 
centrifuging at approximately 125x g for 10 min at 4°C.  % viable cells were then counted 
using a hemocytometer and trypan blue (final concentration 0.32%).  Male athymic nude 
mice (nu/nu, 5-week-old, Charles River) were subcutaneously injected with 5×106 LNCaP 
(PSMA+) cells or 1×106 DU145 (PSMA-) cells, suspended in 100 µl of 1:1 (v/v) 
HBSS/Matrigel (Becton Dickinson) mixture, on both flanks.  Tumor volumes were measured 
with digital caliper every three days and calculated as V = (L × W2)/2 assuming ellipsoid 
tumor shape.  When the tumor volume reached 100-150 mm3 (10-14 days), the mice were 
randomized into groups with similar mean tumor volume for in vivo imaging and efficacy 
studies. 
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In Vivo Imaging and Biodistribution Study in Mouse Xenograft Model.  Mice 
(n=3) bearing LNCaP (PSMA+) and DU145 (PSMA-) tumors received either vehicle (1% 
DMSO, 99% sterile saline), TFM1 (17 nmol/kg) or BFM1 (17 nmol/kg) in vehicle via tail 
vein injection.  In vivo fluorescence imaging was performed on one animal from each group 
together for both tumor models at 1, 4, 24, 48 and 72 h post-injection on LI-COR Odyssey® 
CLx Imaging System at excitation and emission wavelength 685 and 800 nm, respectively.   
After 72 h, animals were sacrificed and tumors, liver, kidney, heart and blood were collected, 
rinsed with PBS buffer, and weighed.  Ex vivo fluorescence imaging and quantitative 
analysis were performed on the collected organs for biodistribution study using LI-COR 
Odyssey® CLx Imaging System and Image Ready software supplied with the instrument.  
Mean (±s.d.) AFU/mg values were calculated for all collected organs and blood. 
In Vivo Efficacy in Mouse Xenograft Model.  Mice (n=6) bearing LNCaP 
(PSMA+) and DU145 (PSMA-) tumors received either vehicle (5% Ethanol, 10% PEG 400 
and 85% sterile water) or test compounds (either TFM3, BFM2 or MMAE, at a dose of 300 
nmol/kg) in vehicle via intraperitoneal injection, every three days, total 4 doses.  Body 
weight, tumor volumes, food and water intake was recorded every three days for 14 days.  
After 14 days, animals were sacrificed, all tumors were excised and weighed. 
Statistical Analysis.  All results are expressed as mean ± s.d. Statistical analysis was 
performed with GraphPad PRISM 8 software.  The significance of the differences were 
measured by One-Way ANOVA followed by Tukey’s multiple comparison test (ns, not 
significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). 
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